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Development of a DNA Vaccine Against Streptococcus mutans: a Novel Approach to 
Immunization Against Dental Caries 
Thomas K. Han  
ABSTRACT 
Streptococcus mutans is the main causative agent of dental caries, which is a 
widespread infectious disease.  A number of surface molecules are involved in the 
pathogenicity of this organism, including adherence and aggregation factors.  The wall-
associated protein A (WapA) of Streptococcus mutans GS-5 was previously 
demonstrated to be a sucrose-dependent adherence and aggregation factor, and is a larger 
precursor to extracellular antigen A (AgA), a candidate antigen for a dental caries 
vaccine. 
The full-length wapA gene and a C-terminal truncated version agA encoding the 
AgA were cloned into the mammalian expression vector pcDNA 3.1/V5/His-TOPO. The 
above constructs were mixed with a cationic lipid and used to transfect Chinese hamster 
ovary (CHO) cells.  Transient expression of the wapA and agA genes was observed at 24 
h post-transfection, as shown by Western immunoblot analysis.  In CHO, cells WapA 
containing the membrane and wall-spanning region was found in apoptotic bodies, 
whereas the soluble AgA, which lacked the hydrophobic region, was found in 
extracellular medium.  
A higher salivary IgA level was observed in mice immunized with the pcDNA-
          x
wapA vaccine as compared to those immunized with the pcDNA-agA vaccine.  
Furthermore, the anti-WapA antibody inhibited S. mutans sucrose-dependent adherence, 
suggesting potential protection of the tooth against S. mutans colonization, while anti-
AgA had no significant effect.  Indeed, prediction and analysis of protein epitopes 
showed that WapA contains highly promiscuous MHC-II binding motifs that are absent 
from AgA.  Immunodot assay confirmed that WapA bound biotin-labeled dextran, 
whereas AgA did not. These data indicated that full-length wall-associated WapA is a 
better candidate vaccine antigen than the soluble AgA. 
 In co-immunization studies pcDNA-ctb was preferable to pcDNA-il-5 as genetic 
adjuvant.  A comparable secondary response was obtained by priming with either 
pcDNA-wapA or WapA followed by a WapA boost, thus demonstrating the pcDNA-
wapA as a valid contender primary vaccine.  The successful utilization of the caries 
DNA-based vaccine protocol would represent a highly significant new approach to this 
important worldwide health problem. 
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INTRODUCTION 
Background of Dental Caries 
Dental caries is one of the most prevalent and costly chronic infectious diseases in 
humans.  Despite improvement in dental hygiene and advances in caries research over the 
past decades, dental caries has been experienced by over 90 percent of all adults in the 
U.S. and over 80 percent of children by age 17, resulting in billion of dollars in health 
expenditures per year (53, 79, 140).  In recent years, caries prevalence and distribution 
has shifted from being circulated evenly among the population, to disproportionately 
affecting individuals in economically-challenged populations with more severe forms of 
caries (20, 108).  The incidence of dental caries is high in industrialized countries and on 
the rise in developing countries (4, 71).  The risk of severe dental caries is increased in 
elderly people who are showing root-surface caries and in other specific groups such as 
those who suffer from hypo-salivation due to drug-induced side effects, systemic disease 
such as Sjogren’s Syndrome, and tumor patients receiving irradiation therapy (2, 3, 13, 
128).   
The etiologic role of mutans streptococci (MS) in dental caries was established in 
Keyes’ experiment in 1960, showing direct evidence that these organisms are the primary 
etiologic agents.  MS has been divided into eight serotypes designated a-h based on 
differences of carbohydrates in the cell wall (9, 11, 97).  DNA homology analysis further 
clarified MS into seven distinct species – known as Streptococcus mutans (serotypes c,e 
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and f), S. rattus (serotype b), S. cricetus (serotype a), S. sobrinus (serotypes d and g), S. 
ferus (serotype C), and S macacae (serotype c) and S. downei (serotype H) (8, 17, 18, 
138).  These organisms have the ability to colonize the tooth surface, build up dental 
plaque by aggregating homologous and heterologous bacteria, and produce lactic acid 
which attacks the enamel.  Of these species, S. mutans has been implicated as the major 
and most common of the two main etiological agents of human dental caries (37, 73, 
135), the other being called S. sobrinus.  S. mutans was first described by Clarke in 1924 
after he isolated an organism that he felt to be from the initial carious lesions in humans 
(15).  Clarke named S. mutans based on his observation that the organism formed 
different colony morphology with the change of growth media. 
As with a large number of infectious diseases, dental caries is preventable by 
immunization.  This was demonstrated in animal studies, but the prospect for a human 
dental caries vaccine using whole organisms or components of S. mutans has been 
hampered by the presence of antigens that are cross-reactive with proteins in human 
cardiac tissue (46).  Consequently, much effort has been focused on developing 
recombinant vaccine antigens.  Through this process, heart reactive antigens can be 
avoided or modified to eliminate the heart cross-reactive epitopes.  With decades of 
research on S. mutans by dedicated researchers around the world, a number of proteins 
involved in colonization have been studied as important candidate dental vaccine 
antigens.  One concern is how to make them affordable to large populations, especially 
since most of the populations at risk are from developing countries, or from low 
socioeconomic groups in industrialized nations.   
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Virulence Factors of S. mutans and Approaches for Development of Anti-caries 
Vaccine 
A number of surface molecules contribute to the pathogenicity of the MS 
organism including adherence and aggregation factors (37).  With recombinant DNA 
technology and advances in mucosal immunology, a number of virulence factors 
involved in S. mutans, a principal causative agent of dental caries, have been 
characterized, cloned and tested for the ability to induce a protective response through 
induction of mucosal immunity and production of specific salivary secretory IgA (sIgA).  
Today, much progress has been made in the field of dental caries vaccines based on the 
virulence factors involved in the S. mutans colonization of the tooth and build-up of 
dental plaque (Fig. 1).  The factors tested to reduce dental caries in an animal model 
include: (1) A 190 kDa salivary adhesin called “AgI/II”; (2) Glucosyltransferase (GTF);  
(3) A glucan binding protein (GBP),  (4) A 29 kDa extracellular antigen A (AgA), also 
known as antigen III; and (5) Wall-associated protein A (WapA), a precursor to the 
extracellular AgA (59, 64).  These receptors could be blocked by vaccine-induced 
antibodies, thus preventing the S. mutans from colonizing or accumulating in the oral 
cavity.  Recombinant DNA technology has been applied to clone the genes encoding the 
above virulence factors for the production of recombinant antigen and peptide vaccines, 
as well as avirulent recombinant organisms expressing the target antigen.   
 
 
 
 
  
 
FIG. 1.  Virulence factors of Streptococcus mutans during colonization and accumulation 
in dental biofilms. 
 
AgI/II 
A 190 kDa major cell-surface protein antigen of S. mutans has been variously 
known as AgI/II, P1 (33), Pac (93), and AgB (110) while designated as SpaA or PAg (55) 
in S. sobrinus.  AgI/II is involved in the initial bacterial adherence to tooth surfaces (28, 
109).  The AgI/II contains two internal repeating amino acid regions: 1) A-region with an 
alanine-rich tandem repeat at N-terminal domain that can bind salivary components such 
as sIgA, β2-microglobulin, histidine-rich polypeptides, a 60 kDa glycoprotein, high 
molecular mass glycoproteins, lysozyme, lactoferrine, and 2) a P-region with a proline-
rich repeat in the center of the molecule where an adhesion epitope resides (19, 68, 87).  
         4
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Antibody to intact AgI/II (38, 54, 69) or peptides containing salivary-binding domain 
epitopes (131) induced partial protection against dental caries in rodents, primates, and 
humans.  Passive immunization with the anti AgI/II antibody have shown reduced tooth 
colonization with S. mutans (75, 76). 
Glucosyltransferases (GTF) 
Glucosyltransferases (GTF) in S. mutans are involved in the synthesis of 
extracellular glucans, and its role in sucrose-enhanced cariogenicity was obtained from 
the comparative insertional inactivation study of GTF genes (86, 144).  Three gtf genes 
encoding GtfB, GtfC and GtfD are responsible for glucan systhesis in S. mutans: GtfB 
(118) synthesizes an α-1,3-linked insoluble glucan,  while GtfD (44) is involved in the 
formation of a soluble α-1,6 linked glucan.  GtfC (100) synthesizes both insoluble and 
soluble glucans.  All GTF molecules contain a glucan-binding domain (GLU) on the C-
terminal end and a sucrose-binding catalytic region (CAT) on the N-terminal part (84).  
Salivary and serum antibodies to GTF were detected and significant protection from 
dental caries was obtained by oral immunization with GTF in an animal model (126, 
127).   
Synthetic peptides from the catalytic or glucan-binding domains of GTF have 
been shown to induce protection against experimental dental caries (132).  The newly 
formulated GTF peptide vaccine containing both the catalytic (CAT) and glucan-binding 
(GLU) regions induced significantly enhanced levels of antibody to GTF than either a 
CAT or GLU construct or coimmunization with CAT/GLU (133). 
Glucan-binding proteins (GBP) 
The S. mutans  glucan-binding protein (GBP), which mediates binding of the 
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organisms to glucans synthesized by GTFs, is a virulence component in the development 
of dental plaque, and a candidate for a human caries vaccine (72).  S. mutans synthesizes 
three glucan-binding proteins: GBP-A (110), GBP-B (123), and GBP-C (116).  The 
predominant S. mutans GBP-A with a molcular mass of 74 kDa was purified (112), 
cloned, and sequenced (5).  A S. mutans mutant insertionally inactivated in the gbpA was 
analyzed in vitro to demonstrate the role of gbp in colonization (6).  Both the mutant and 
the parental type colonized smooth surfaces when grown in the presence of sucrose, 
suggesting that S. mutans may involve more than one protein in glucan binding. 
GBP-B secreted by S. mutans having a molecular mass of 59 kDa has been 
purified (123) and compared structurally and antigenically to other GBP-A in S. mutans 
and to the glucan-binding region of S. mutans glucosyltransferases.  The GBP-B was 
shown to be antigenically distinct from the GBP-A and induced significantly higher 
salivary immune response in humans (123).  GBP-C has an estimated molecular mass of 
64 kDa and has no sequence similarities to GBP-A or GTF, but shows significant 
sequence matching to the surface protein adhesion AgI/II (77, 125).   
Antigen A (AgA) 
One candidate vaccine antigen against dental caries is the S. mutans antigen A 
(47, 110, 111), a proteolytic cleavage product of the large precursor wall-associated 
protein A (WapA) (23, 113).  Immunization with AgA-induced protection against caries 
has been performed on cynomolgus monkeys (111) and mice (47) and has been 
recognized as an anti-caries vaccine.  
Wall-associated protein A 
The gene encoding the wall-associated protein A (WapA), a precursor to the AgA, 
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was cloned and sequenced and proven to be involved in S. mutans sucrose-dependent 
adherence and aggregation (23, 30).  Insertional inactivation of the wapA gene resulted in 
a significantly reduced sucrose-dependent adherence and aggregation, 40 and 52%, 
respectively, of the wapA mutant (101).  These findings suggest that the antibody to the 
WapA or AgA may prevent dental caries by blocking both the colonization of the tooth 
and the build-up of dental plaque by S. mutans.   
A genomic library of S. mutans strain GS5 was constructed in our laboratory via 
the shuttle vector Streptoccus-E. coli pSA3, and one clone was found to express the AgA 
and its precursor, the WapA, by Western immunoblot analysis using a monoclonal 
antibody against AgA (22).  Subsequent sequence analysis of the gene showed that AgA 
was derived from WapA by proteolytic cleavage.  AgA previously shown by Russell 
(110) was a good candidate dental vaccine antigen (47, 111).   Immunization of rats and 
monkeys conferred protection in these animals, with a reduction in carious lesions upon 
infection of these animals with the S. mutans and feeding a cariogenic diet rich in sucrose 
content.  
 Since WapA has been observed to have binding affinity for dextran, this protein 
may be involved in glucan-mediated adherence and aggregation.  Indeed, insertional 
inactivation of wapA in S. mutans caused a significant decrease in sucrose-dependent 
adherence and aggregation, by 40% and 50% respectively, as compared to the wild type 
tested in parallel (101).  The role of WapA in sucrose-dependent adherence and 
aggregation was further demonstrated by cloning the wapA gene into S. gordonii, a 
heterologous organism known to produce GTF but devoid of WapA.  Expression of 
WapA conferred to this organism the ability to attach to a culture dish and to aggregate 
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when grown in BHI containing 4% sucrose. 
 These observations provided an explanation of the protection obtained by 
immunization with AgA (111).   Perhaps the antibody raised against AgA blocked S. 
mutans adherence and aggregation through binding to WapA.  Through comparative 
sequence analysis between the S. mutans strain GS5 and the S. mutans strain, Ingbritt 
showed that the wapA gene was virtually identical in these strains, with the exception of 
a 24 base pair deletion in the GS-5 strain.  This is in agreement with the immunological 
cross-reactivity of both strains with a rabbit anti-WapA antibody. 
Isolation of WapA from the original E. coli recombinant clone designated 4B2 
was not efficient; therefore, production of vaccine using this clone is not practical for 
large scale immunization studies.  To increase the expression of WapA and to facilitate 
its isolation twelve wapA truncations were prepared by PCR amplification using primers 
designed to delete various regions of the wapA gene.  The truncated wapA genes, 
designated wapA-A to wapA-L were cloned into the TA cloning vector pCR2.1-TOPO 
(Invitrogen, Carlsbad, CA).  Then they were excised by digestion with EcoRI and cloned 
into the expression pGEX-6P-1 glutathione S-transferase (GST) fusion vector 
(Pharmacia, Pittacaway, NJ).  Cloning of a series of truncations of the wapA gene at the 
N-terminal and C-terminal ends into the expression fusion vector pGEX-6P-1 glutathione 
S-transferase (GST) demonstrated that the WapA and AgA reacted most strongly with a 
rabbit antibody to the S. mutans WapA (146).  The resulting plasmids were used 
separately to transform E. coli BL21, a protease-deficient host strain for optimal 
expression of recombinant proteins (Pharmacia). 
PGEX-6P-1 contains a tac promoter for inducible high-level intracellular 
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expression, an internal lac Iq repressor for induction with isopropyl beta-D-
thiogalactoside (IPTG), a PreScissionTM protease cleavage site for removal of the GST by 
the PreScission protease enzyme, and an ampicillin resistance gene for selection of 
recombinants.  Of the 12 truncated wapA constructs, eight truncated wapA were found to 
express proteins reacting with a rabbit anti-WapA.  These included wapA-D to wapA-K.  
The twelve wapA constructs are presented in Fig 2.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
FIG. 2.  Construction of truncated wapA.  Numbers on the top of the line represent amino 
acid positions.  P is the promoter; SP is the signal peptide; PC is the protease cleavage 
site; W is the Cell wall domain; and M is the Membrane-spanning domain. 
 
Two of the clones constructed are of interest to the present study since they 
expressed proteins corresponding to the wild type full-length WapA (clone WapA-E), 
and a proteolytic cleavage site corresponding to the wild type extracellular AgA (clone 
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WapA-G) (146). 
Passive immunization 
Passive immunization has also been considered as a safe way to administer a 
dental vaccine.  Specific polyclonal and monoclonal antibodies prevent colonization of 
the teeth by S. mutans.  Lehner et al. (67) obtained a decrease in colonization by repeated 
application of a monoclonal antibody to S. mutans AgI/II onto the teeth of Rhesus 
monkeys.  Passive immunization by oral administration of antibody to GTF-generated 
protection was performed against S. mutans in the rat model (124).  Other studies 
demonstrated a more convenient means of passive immunization with immunized cow’s 
milk.  Application to mice showed a significant decrease in caries activity as compared to 
animals receiving milk from unimmunized cows (91).  Hatta and Michalek (42) showed 
that a mouth rinse containing egg yolk IgY from chicken immunized with whole S. 
mutans prevented the in vitro attachment of the S. mutans to saliva-coated hydroxyapatite 
and reduced plaque formation in human volunteers.  Ma et al. (76) ingeniously used a 
tobacco plant as a means to mass produce monoclonal sIgA.  Application of the plant-
derived antibody to human volunteers reduced plaque formation.   
Advantages and disadvantages are associated with each type of vaccine.  Long-
term protection is obtained with active immunization using recombinant proteins or 
peptides, but the response is variable between individuals.  Rapid and dependable 
protection is obtained with passive immunization; however, this protection is of limited 
duration and frequent booster applications of antibodies may be required. 
Advantages and Risks of DNA-based Immunization 
DNA vaccines possess many of the most attractive aspects of modern vaccination 
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strategies and, therefore, offer potential solutions for other diseases for which 
conventional vaccines have not yielded preventive measures.  In comparison with 
traditional vaccines, DNA-based vacccines offer a major advantage in terms of the ease 
with which they can be constructed, modified, and purified.  DNA vaccines are much 
more stable and can be manufactured inexpensively on a large scale at high levels of 
purity, which make them ideal prophylactic agents for use in developing countries (24, 
129).  Moreover, many different antigens from the same or different pathogens can be 
cloned into a single vector.  Therefore, making multivalent vaccines against pathogens 
will decrease the number of vaccinations necessary, especially in children (27, 82). 
Since DNA vaccines utilize the host cell’s transcriptional and translational 
machinery to produce conformationally-specific antigens, the native conformation of 
epitopes is conserved.  An appropriate tertiary structure of protein conserved following 
administration of a DNA vaccine is essential for the induction of conformationally 
specific antibodies and protective immunity (36, 117).  DNA vaccines can initiate both 
cellular and humoral immune responses that are long lasting (24, 61, 103).  
To date, DNA vaccines have not shown any of the possible adverse effects that 
have been previously discussed as potential safety issues associated with DNA-based 
immunization, which include the integration of the plasmid DNA into the host genome 
(88, 141), leading to insertional mutation, induction of tumor formation by activation of 
oncogenes, or auto-immune disease due to the induction of anti-DNA antibodies (66, 
143).  The safety of DNA vaccines in humans has been demonstrated in clinical trials 
against several diseases and specific pathogens including cystic fibrosis, the hepatitis B 
virus, herpes simplex virus, HIV, malaria, and cancer (26, 78, 136). 
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Mechanism of DNA Vaccines 
The cellular and molecular mechanisms by which DNA-based immunizations 
stimulate different types of T-cells have not been fully elucidated (64).  The type of cells 
transfected may vary depending on the route and method of DNA delivery (61).  After 
administration of antigen-encoding plasmid DNA, the vaccinee’s cells take up the DNA 
molecules and transport them to the nucleus for transcription, with eventual export of the 
transcribed messenger RNA to the cytoplasm for protein synthesis.  In the nucleus, the 
plasmid DNA is retained in an extra-chromosomal location and thus an expression of the 
DNA is not influenced by surrounding chromosomal elements (39). 
After translation at the ribosome, the antigens expressed intracellularly are 
processed and presented to T cells in the context of antigen presenting cell’s (APC) MHC 
class I or II molecules, depending on whether the antigen is processed through an 
exogenous or endogenous pathway (106).  An antibody response is induced by secretion 
of expressed whole antigen or antigen peptides processed and presented to CD4+ T cells 
on the cell surface with host MHC class II by antigen-presenting cells.  Transfected APC 
can also process the antigen to peptides which bind to an MHC class I molecule in the 
ER.  This complex moves via the golgi apparatus to the cell surface where it can 
stimulate the cellular T cell response by activation of CD8+ cytotoxic T lyphocytes 
(CTL), which directly lyse infected target cells (104) (Fig. 3). 
 
 
 
 
  
 
FIG. 3. Genetic immunization: Mechanisms of antigen presentation.    
 
Mucosal Immune System and Salivary Immunity in the Oral Cavity 
The mucosal surfaces provide the principal immune defense against most human 
pathogenic organisms.  Mucosal immunity to a variety of antigens has been successfully 
induced by immunization with protein or DNA vaccine through mucosal routes including 
oral, nasal, and genito-rectal mucosa (134).  The major antibody isotype found in external 
secretions is sIgA, which can traverse epithelial membranes and help provide specific 
immunity against pathogens, including cariogenic S. mutans (37).  All the mucosal routes 
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tested induced the production of secretory IgA in the immunized area, as well as at 
distant mucosal surfaces (84, 90). 
One major function of the mucosal immune system is to develop salivary IgA 
antibodies in newborn infants (34).  In mucosal immune systems, antigens or 
microorganisms are taken up by specialized epithelial cells termed M cells which overlie 
organized lymphoid follicles in tonsils and adenoids (Waldeyer’s ring) and on intestinal 
Peyer’s patches.  After uptake and transcellular transport by the M cells, the antigenic 
materials are processed by underlying APCs, which present them to T helper cells.  B 
cells are stimulated by both T-cell activation and specific cytokines.  B cells then, 
differentiate into precursors of IgA-secreting plasma cells. 
Following activation of B and T cells, the IgA-producing cells migrate to various 
mucosal effector sites in the mucosal tissues including the stroma of the salivary glands, 
where terminal differentiation of the B lymphoblasts into IgA-secreting plasma cells 
occurs under the regulation of cytokines secreted by the T cells and epithelial cells.  The 
resulting polymeric IgA secreted in the salivary glands is taken up by a polymeric Ig 
receptor on the basolateral surface of glandular epithelial cells and released into the saliva 
with a bound secretory component to form salivary sIgA (81, 84, 90).  Secreted salivary 
IgA, in turn, interferes with S. mutans binding to tooth surfaces via both sucrose-
independent and sucrose-dependent mechanisms (122).  Immunoglobulins derived from 
circulation pass through the gingival crevice into the oral cavity.  These Igs, which 
include IgM, IgG, and IgA, are proportionally lower than sIgA in saliva compared to 
relative proportions in blood plasma (37).   
 
          16
Caries Vaccine Route to Mucosal Immune Response 
Depending on the route of immunization and the type of adjuvants utilized, 
development of systemic and/or mucosal immunity can be favored.  Induction of specific 
mucosal immunity with production of specific salivary IgA is the goal of a dental vaccine 
(37, 122).  In mucosal system, the delivery of vaccine at any mucosal route results in the 
induction of secretory IgA antibody at the delivery site as well as in the distant mucosal 
sites (90).  Oral immunization induces mucosal immune response in the gut-associated 
lymphoid tissues (GALT), one of the principal inductive sites of sIgA antibody response, 
which consist of the Peyer’s patches, the appendix, and solitary lymph nodes in the 
gastrointestinal tract (83). 
One drawback of the oral route for immunization is the damaging effects of 
stomach acidity on the antigen.  Thus, for oral immunization, the DNA vaccine has to be 
encapsulated in enteric-coated tablets, or delivered by intra-oral Jet in the cheek, which is 
also the case with protein vaccines (74).  Rectal immunization is also an effective 
inductive method for a mucosal immune response.  Inductive potential of the rectal route 
for salivary IgA responses was considered as an alternative route to mutans streptococcal 
antigens (65). 
Of all the mucosal routes tested, intra-nasal application of protein or DNA 
vaccines has gained much popularity because it is not invasive (32, 38, 51, 92).  This 
route is especially convenient for the immunization of young children, who cannot yet 
swallow enteric-coated tablets.  Furthermore, unlike oral vaccine, a nasal vaccine does 
not need to be encapsulated into enteric-coated tablets and consequently costs less to 
prepare. 
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Intranasal immunization with a S. mutans glucan-binding region of 
glucosyltransferase (51) and a S. mutans-enriched fimbrial preparation (32) elicited 
specific salivary IgA production and protective immunity.  Intranasal immunization with 
a DNA vaccine mixed with cationic lipids has been shown to be immunogenic.  
Immunization of animals with a luciferase gene-DNA construct complexed with cationic 
proteins resulted in the expression of luciferase in nasal tissue and an induction of a 
systemic and humoral response after a single dose of the vaccine (58).   
A number of adjuvants have been identified as stimulating a mucosal response to 
protein or DNA vaccines.  Adjuvants used in protein or peptide vaccines include cholera 
toxin CT, cholera toxin B subunit (CTB), and a detoxified heat labile E. coli toxin (LT 
R292G) (25, 142).  Adjuvants used in DNA vaccines include liposome and various 
cationic lipids (57, 58, 89, 98).  Further stimulation of the immune response may be 
obtained by co-immunization with genetic adjuvants consisting of plasmids encoding 
cytokines, for example IL-4 or IL-10, to induce a Th2 type response, or IL-12 and/or a 
granulocyte/macrophages colony stimulating factor to obtain a Th1 type of response (27, 
92, 102, 139). 
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MATERIALS AND METHODS 
Structural Analysis of the Wall-associated Protein A Gene (wapA) 
Antigenicity prediction algorithms of the WapA protein 
The identification of B cell epitopes within a WapA protein sequence was 
analyzed using four different prediction algorithms: Hopp-Woods, Parker, Welling, and 
Kolaskar and Tongaonkar.  The hydropathic profile of the WapA was calculated using 
the Hopp-Woods algorithm (45), which is assumes that antigenic sites are primarily 
hydrophilic at the surface of the protein.  The Parker method (96) of prediction uses an 
experimentally-determined hydrophilic scale of polypeptides derived from high-
performance liquid chromatography (HPLC) parameters for the antigenic determinants.  
Prediction of antigenic regions using the method of Welling (137) is based on the amino 
acid composition in known antigenic peptides.  A semi-empirical algorithm of Kolaskar 
and Tongaonkar (60) uses data from both experimentally-determined epitopes and 
physicochemical properties of amino acids for the prediction of antigenic determinants.  
Prediction and analysis of MHC Class II binding regions 
Potential T cell epitopes within AgA or WapA were identified using a matrix-
based quantitative algorithm, publicly available on line at 
http://www.imtech.res.in/raghava/propred/.  The promiscuous binding regions were 
located and quantified by a virtual matrix for 51 known MHC class II alleles.  Binding 
probabilities were set at a 3% threshold representing the 3% best scoring natural peptides.   
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Analysis of wapA DNA sequence for glycosylation 
Inappropriate glycosylation of bacterial proteins that results in conformational 
change, thus causing alteration or loss of immunogenicity, has been of concern in DNA 
vaccine preparation (48, 50).  Potential glycosylation sites of the WapA protein were 
evaluated.  Prediction analysis of the N-glycosylation or O-glycosylation sites in WapA 
based on the amino acid sequence was performed using NetNGlyc (35) or a NetOGlyc 
prediction server (40, 41) available from URL: http://www.cbs.dtu.dk/services/. 
Kozak sequences on the 5′ untranslated region (UTR) of the mRNA transcript 
Initiation of translation is regulated by two fundamentally different mechanisms 
in prokaryotes versus eukaryotes.  In prokaryotes, the ribosome binding site (RBS), also 
called the Shine-Dalgarno sequence, is engaged in its recognition by ribosome for 
efficient and accurate translation of mRNA.  In eukaryotes, however, a 40S ribosomal 
subunit locates the initiator AUG codon by scanning the mRNA from the capped 5′ end 
for the first AUG codon.  It has been proven that a specific translational initiating 
sequence called the Kozak consensus sequence is required for efficient translation 
initiation in higher eukaryotes (62).  Prokaryotes and some eukaryotes do not have a 
Kozak sequence in their genes.  To improve the translation efficiency of an expressed 
wapA gene in mammalian hosts, the Kozak sequence ANNATGG was incorporated into 
the wapA or agA forward primer in the process of caries DNA vaccine construction. 
Codon usage 
Codon usage was another topic of concern in bacterial DNA vaccine 
development.  There is a significant variation of codon usage bias in all organisms and 
even between different genes.  The difference in the codon usage can seriously limit the 
          20
gene expression efficiency in a heterologous system.  Codon optimization may be 
considered in case the expression of the cloned gene is hampered due to the codon bias.  
In such case, the alteration of rare codons of the foreign gene to make codon usage match 
the available tRNA pool within the host cell may benefit by improving the expression 
rate of heterologous genes. 
Commonly used codons for S. mutans serotype c or wapA were determined from 
the Codon Usage database located at www.kazusa.org.jp/codon/ and analyzed against 
that of Homo sapiens or Mus musculus using the graphical codon usage analyzer 
available at www.gcua.de.  To locate cumulative low codon usage from wapA, each 
codon position of wapA sequence was analyzed against the codon usage table of Homo 
sapiens or Mus musculus using the codon usage analyzer.  Codons were optimized 
according to the codon usage tabulated from GenBank.   
Identification and Characterization of Collagen Binding Properties by the WapA 
Bacterial strains and growth conditions 
The S. mutans strain used for cloning and expression was GS-5 (serotype c) (our 
laboratory stock).  S. mutans were grown in brain heart infusion (BHI) (Fisher Chemical 
Co., Cincinnati, OH) broth at 37 °C without agitation, or on BHI agar containing 1.5% 
agar at 37 °C in the presence of 10% CO2.  
Specificity and localization of collagen binding domain  
The nucleotide sequence and the deduced amino acid sequence of wapA indicated 
that it contained a sequence specific collagen binding domain.  Further analysis on the 
specificity and localization of the collagen binding domain of the WapA was performed 
with different functional domain algorithms including the NCBI Conserved Domain 
          21
Database (CDD) (80) and Protein Families (Pfam) Applications (7) of these programs.   
Structure prediction of collagen binding domain in WapA  
In order to investigate the biochemical function of the putative collagen binding 
domain, secondary structure analysis was carried out with the 3D-PSSM program (31, 
56) using the amino acid sequence of the putative collagen binding domain in the WapA.  
The predicted secondary structure was matched against the 3D-PSSM fold library 
(http://www.sbg.bio.ic.ac.uk/~3dpssm/), which contains solved crystal structures.  The 
protein sequence was also scanned against the SCOP (Structural Classification of 
Proteins) database, where protein domains are classified into four levels: family, 
superfamily, fold, and class (72). 
Cloning, expression and purification of recombinant collagen binding domain (rCBD) of 
WapA 
A C-terminal truncated version of wapA (wapA-G) encoding the AgA was used 
as a clone for a putative recombinant collagen binding domain (rCBD).  A 885 bp DNA 
fragment of wapA lacking the promoter, the signal sequence, and the hydrophobic C-
terminal region was cloned into the pGEX-6P-1 glutathione S-transferase (GST) fusion 
vector and hosted in E. coli BL21 (DE3).  rCBD was overexpressed by inoculating 500 
mL of 2x YTA medium with 5 ml of overnight culture.  The culture was continuously 
grown at 37 °C until the A600 reached around 1.  IPTG was added to a final concentration 
of 1 mM to induce the expression of the cloned gene. 
At 6 h post incubation, the cells were harvested by centrifugation at 7,700 x g for 
10 min at 4 °C, and washed with 250 ml cold PBS containing 1 mM 
Phenylmethylsulphonylfluoride (PMSF), followed by 1 min sonication on ice and 
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centrifugation at 12,000 x g for 30 min.  Solubilization of the fusion protein was aided by 
mixing 20% Triton X-100 for 30 min.  After centrifugation at 12,000 x g for 10 min at 4 
°C, the supernatant was incubated on a rocker for 30 min at room temperature with 2 ml 
of the 50% slurry of Glutathione Sepharose 4B (Pharmacia). 
The mixture was transferred onto the Sepharose column, and the column was 
washed with 15 ml of PBS.  After the column was washed with 2.5 ml of PreScission 
cleavage buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, pH 
7.0), the PreScission Protease mix containing 20 µl of PreScission Protease with 230 µl 
of PreScission cleavage buffer was loaded onto the column and incubated on a rocker at 5 
°C for 4 h to cleave off the GST tag.  The unbound rCBD protein was eluted with 800 µl 
of PreScission cleavage buffer.  Eluted fractions containing rCBD protein were analyzed 
by SDS-PAGE.   
Biotin Labeling 
Biotin labeling of the purified rCBD was performed with Sulfo-NHS-LC-Biotin reagents 
(Pierce, Rockford, IL) as follows.  rCBD in an amine-free elution buffer (pH 7.2) was 
mixed with a 10-fold molar excess of 10 mM sulfo-NHS-biotin reagent solution with the 
protein, and the mixture was incubated at room temperature for 1 h.  To remove free 
biotin, the reaction solution was dialyzed against 3 changes (4 L each) of PBS (pH 7.3) 
overnight using dialysis tubing with a nominal Molecular Weight Cut Off 's (MWCO) 
12,000 – 14,000. 
Dot Blot Collagen binding assay 
To test the ability of WapA to bind to collagen, a soluble native type I collagen (Sigma, 
St. Louis, MO) was diluted in PBS to 5 µg/ml and was dotted (10 µl per dot) onto a piece 
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of nitrocellulose membrane.  The membrane was blocked by incubation with 5% skim 
milk in PBS to which biotin-labeled rCBD was added, and incubated for 1 h at room 
temperature.  After extensive washes with PBST (PBS with 0.05% Tween 20), the bound 
protein was detected by alkaline phosphatase-conjugated streptavidin (AP-streptavidin) 
(Sigma) diluted 1:1,000 which was incubated in PBS for 1 h at room temperature.  After 
a final wash in PBS-T, the membrane was stained with a chromogenic substrate (25 mg 
o-dianisidine tetrazotized, 25 mg Naphthyl acid phosphate in sodium borate buffer, pH 
9.7 contaiing MgSO4-7H2O added at 1.2 mg per ml).  Bovine Serum Albumin (BSA) on 
the dot was tested in parallel as a negative control.   
Solid Phase Binding Assay 
To further evaluate the binding abilities of WapA to an immobilized native type I 
collagen, an ELISA assay was carried out as a function of collagen concentration.  Native 
type I collagen (Sigma, St. Louis, MO) was diluted in PBS at a concentration of 5 µg/ml, 
and coated onto 96 well microtiter plates (Immobilon IV from Dynex, Chantilly, VA) 
overnight at 4 °C.  After rinsing of the plate with PBS-T, the wells were blocked with 200 
µl of 10% skim milk in PBS containing 0.02% sodium azide, for 1 h at room temperature.  
100 µl of various dilutions (1 µg to 12 µg) of biotin-labeled, purified rCBD without a 
GST tag was added separately to the wells and the plate was incubated at 37 °C for 1 h. 
The wells were washed with PBS-T and incubated with AP-streptavidin diluted 
1:20,000 in PBS for 1 h at room temperature.  The absorbance at 405 nm of each well 
was recorded using an ELISA reader against a PBS-coated well used as a blank.  Wells 
coated with BSA served as a control for nonspecific binding.  Binding properties were 
calculated and plotted as a function of the dose of protein rCBD.  
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Construction of DNA vaccines 
Cloning of the wapA and agA genes into the eukaryotic expression vector 
pcDNA3.1/V5/His-TOPO 
The wapA and agA were obtained by PCR amplification of a previously 
constructed (145) plasmid pGEX-6P-GST containing wapA-E and wapA-G gene 
encoding WapA and AgA, respectively, using the following two sets of primers: 
wapA: 
Forward: 5’-ACC ATG GAC CAA GTC ACA AAT TAT ACA-3’ 
Reverse: 5’-TTA TTA GCA TTA TTA TCA ATG TTA-3’ 
agA: 
Forward: 5′-ACC ATG GAC CAA GTC ACA AAT TAT ACA-3′ 
Reverse: 5′ -TTA GTA GCC TGT TTG ATT GGA-3′ 
The initiation codon ATG was included in each forward primer to ensure 
expression in eukaryotic cells. The PCR was performed as described below.  The Kozak 
consensus sequence ANNATGG was also inserted into wapA or agA forward primer to 
increase the expression level of the genes.  The plasmid used for cloning was engineered 
to contain the pUC origin for replication and an ampicillin resistance gene for 
propagation in the E. coli cells. 
To obtain the expression of the cloned gene in mammalian cells the plasmid was 
constructed so that the cloned gene was under the control of a strong viral promoter, 
while the stability of the mRNA was provided by sequences downstream from the 
polylinker consisting of a polyadenylation signal and transcription termination sequences 
from the bovine growth hormone gene.  The PCR products (Fig. 4) were ligated 
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separately to pcDNA3.1/V5/His-TOPO employing the human cytomegalovirus (CMV) 
immediate-early promoter/enhancer (Fig. 5). 
The resulting DNA constructs were transferred into E. coli Top 10 cells by the 
heat shock method as described by the manufacturer (Invitrogen). The transformed cells 
were plated on LB agar containing ampicillin, and the resultant colonies were cultured 
and screened by plasmid DNA isolation, followed by digestion with BstXI and analysis 
by agarose gel electrophoresis. The PCR amplification, using vector sequence as a 
forward or a reverse primer (specific to the T7 sequence or BGH Reverse primer site, 
respectively), and the insert sequence (forward or reverse primer listed above), was 
performed to test the correct orientation of the cloned gene in relation to the vector. 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                   
 
 
FIGURE. 4.  PCR-generated wapA-E and wapA-G genes.  The wapA was amplified by 
PCR.  The location of the terminal amino acid positions and the letter designation of the 
corresponding constructs are indicated.     
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FIGURE. 5.  Map of pcDNA3.1/V5-His-TOPO with wapA insert.  The wapA-E and 
wapA-G were inserted into this vector at the TA cloning site and transformed into E. coli 
Top10.   
 
 
PCR 
PCR was performed for each sample with a 50-µl reaction mixture containing 1.5 
mM MgCl2, 0.125 mM dNTP mixture, 1 U of Taq DNA polymerase, 50 pmol of each 
primer, and 100 ng of template DNA.  The PCR reaction was carried out in a gene cycler 
(Bio-Rad, Hercules, CA) programmed for an initial denaturation step of 3 min at 95°C 
and 30 cycles each of 30 s at 95 °C, 45 s at 54 C, and 1 min at 72 °C, with a final 
extension of 10 min at 72 °C.  The PCR products were visualized on 1% low melting 
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point agarose gel containing ethidium bromide. 
DNA sequencing 
After construction, the plasmids were subjected to sequencing.  Plasmids were 
purified to sequencing grade using the alkaline lysis method described below and 
sequences were determined by DNA sequence analysis conducted at the DNA 
sequencing core facility of the H. Lee Moffitt Cancer Center & Research Institute 
(Tampa, FL).  The primer sets for sequencing were T7 forward primer: 5′-TAA TAC 
GAC TCA CTA TAG GG-3′, and BGH Reverse primer: 5′-TAG AAG GCA CAG TCG 
AGG-3′.  
Optimization of wapA and agA DNA vaccine production and quality control 
Chloramphenicol Amplification of Plasmid DNA containing agA 
Observation of overnight cultures of the recombinant E. coli indicated a striking 
difference in plasmid yield between clones harboring the wapA and agA DNA construct, 
agA clones being much less productive for plasmid isolation.  Clones with the agA 
plasmid construct had the tendency to lyse, therefore decreasing overall plasmid 
production.  To increase the yield of GST-AgA plasmid, chloramphenicol amplification 
of E. coli derived plasmids was used.  250 ml culture of LB medium containing 100 
µg/ml ampicillin was grown and when the culture reached an O.D. of 0.4 at 600 nm, 
chloramphenicol was added to a final concentration of 170 mg/L and incubated further 
for 12 to 16 h at 37 °C with vigorous shaking.  Plasmid production from a 250 ml culture 
without chloramphenicol treatment was performed in parallel with the above condition 
for comparison.   
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Purification of DNA vaccine 
Plasmid DNA was isolated from E. coli TOP-10 containing pcDNA-wapA or 
pcDNA-agA by a modified alkaline lysis method using the Qiagen HiSpeedTM Plasmid 
Maxi Kit (Valencia, CA) and following the manufacturer’s instruction.  Briefly, 
transformed E. coli TOP-10 was grown in batches of a 250 mL LB medium containing 
100 µg/ml ampicillin.  Following overnight (16 h) incubation at 37 oC, cells were 
collected by centrifugation at 6,000 x g for 15 min at 4 oC.  The cells were resuspended 
with the resuspension buffer containing 50 mM Tris.Cl (pH 8.0), 10 mM EDTA, and 100 
ug/ml RNase A and were followed by lysis with the cell lysis buffer containing of 200 
mM NaOH and 1% SDS (w/v) for 5 min at room temperature. 
After neutralization using the neutralization buffer (3.0 M potassium acetate, pH 
5.5), the lysate was filtered and washed with wash buffer containing 1.0 M NaCl, 50 mM 
MOPS, 15% isopropanol (v/v).  Plasmid DNA from the filtered lysate was then purified 
using a pre-equilibrated HiSpeed Tip and eluted in the elution buffer containing 1.0 M 
NaCl, 50 mM MOPS, 15% isopropanol (v/v).  Plasmid DNA was concentrated and 
desalted by isopropanol precipitation and eluted in TE buffer.  Purity and concentration 
of DNA was determined by optical density (OD) reading in UV spectrophotometer at 260 
and 280 nm.  DNA measured larger than 1.7 in the ratio of OD260/OD280 was used in 
this study.  1 OD is equal to 50 µg/mL of DNA. 
Plasmid DNA preparation for immunization study 
Plasmid in TE solution was then concentrated by precipitation with 0.7 volume of 
isopropanol in the presence of 1:10 volume of 3 M Na Acetate (pH 3.0).  The DNA was 
collected by centrifugation at 17,210 g in SS-34 rotor for 10 min at 4 °C, washed with 
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70% ethanol, and centrifuged again for 10 min.  The pellet was dried and resuspended in 
sterile PBS to reach a concentration of 2 mg/ml. DNA purity was assessed 
spectrophotometrically and the ratio of OD260nm /OD280nm was calculated.  DNA 
preparation with a minimum absorbance ratio of 1.7 was used in the present study.  For 
quality control, DNA vaccine constructs were confirmed by BstXI digestions and agarose 
gel electrophoresis, and by DNA sequence analysis conducted at the DNA sequencing 
Core Facility of the H. Lee Moffitt Cancer Center & Research Institute (Tampa, FL). 
Expression of S. mutans Wall-associated Protein A Gene in Chinese Hamster Ovary 
Cells 
Cell culture 
Chinese hamster ovary (CHO) cells were obtained from M. Kimble (Department 
of Biology, University of South Florida, Tampa, FL).  The CHO cells were cultured in 
DMEM supplemented with 10% FBS, 200 mM L-glutamine, 100 mM sodium pyruvate, 
and antibiotics/antimycotic (penicillin 0.5 mg/ml, streptomycin 1 mg/ml, and 0.25 mg of 
amphotericin B/ml of 0.85% saline) at 37°C in 5% CO2.  The E. coli Top 10 cells were 
cultured in Luria-Bertani (LB) broth or on an LB plate containing 1.5% agar.  Ampicillin 
was added at 10 µg/ml for the culture of recombinant E. coli.    
Plasmids 
A gene encoding WapA or AgA was isolated from the plasmid pGEX-6P-GST 
containing wapA-E or wapA-G, respectively, and cloned into the mammalian expression 
vector pcDNA3.1/V5/His-TOPO as described previously.  For isolation and purification 
of plasmid DNA, Qiagen HiSpeedTM Plasmid Maxi Kit (Valencia, CA) was used.  
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Propagation and isolation of Plasmid DNA vector pcDNA3.1/V5-His TOPO 
Propagation of the vector pcDNA3.1/V5-His-TOPO was carried out by 
transformation of E. coli TOP10 using the heat shock method.  When the 50 µl frozen 
competent cells were just beginning to thaw, 100 ng plasmid DNA was added and 
incubated on ice for 30 min.  The cells were heatshock treated by placing them in a 37 °C 
water bath for 1 min and then returned to ice.  After 2 to 3 min on ice, 650 µl LB medium 
was added and the cells were incubated at 37 °C for 1 h in a shaker at 15 rpm.  Then, 25 
to 100 µl of the suspension were aliquoted into the middle of an LB agar plate containing 
100 µg/ml ampicillin and evenly spread over the plate using a spreader.  The plates were 
incubated at 37 °C overnight.  The inserted plasmid DNA vector was isolated by a 
modified alkaline lysis method as described above. 
Transfection of CHO cells 
Transient transfection was performed using the cationic lipid pfx-8 according to 
the manufacturer (Invitrogen).  Briefly, CHO cells were seeded in a 12-well microtiter 
plate at a density of 5 X 104/well and incubated overnight to approximately 50% 
confluency.  The cells were washed by aspiration with sterile PBS, and a transfection 
solution (1 µg of DNA mixed with lipid solution at a 1:6 ratio [v:v]) was added (1.0 ml 
per well).  After 4 h of incubation, the transfection solution was aspirated and replaced 
with an equal volume of complete medium, and the incubation was continued for another 
24 h. On the following day, the cells were detached by scraping, and the cell suspension 
was collected. 
Adsorption of antiserum 
To avoid nonspecific binding of the antiserum to CHO cells, the antiserum was 
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incubated for 1 h at room temperature and then overnight at 4°C with a piece of 
nitrocellulose filter on which CHO cells were immobilized, and the free surface was 
blocked with 10% skim milk in PBS.  The nonbinding fraction was tested by a dot 
immunobinding assay. 
Dot immunobinding assay 
To investigate the expression of wapA and agA in transfected CHO cells, a sonic 
extract (prepared as described below) of each sample was dotted (10 µl per dot) onto a 
piece of nitrocellulose membrane, which was next blocked by incubation with 10% heat-
inactivated horse serum in PBS. The filter was incubated for 1 h with the adsorbed rabbit 
anti-S. mutans cell wall (1:200 dilution in PBS), followed by extensive washing in PBS 
containing Tween 20 added at 0.05% (PBS-T) and a 1-h incubation with a horseradish 
peroxidase-conjugated goat anti-rabbit immunoglobulin diluted 1:1000 in PBS. 
Following an extensive wash in PBS-T, the peroxidase activity was identified using a 
chemiluminescent substrate (ECL for HRP from Pharmacia).  A piece of X-ray film 
(Kodak) was next exposed to the filter for 1 min and developed in a Kodak M35A X-
OMAT processor. 
Western immunoblot analysis of transfected CHO cells 
Expression of WapA and AgA in transfected CHO cells was investigated by 
Western blot analysis as follows.  A sonic extract of the transfected CHO cells was 
prepared using two pulses of 30 sec each in a Vibra CellTM (Sonics & Materials, Inc., 
Danbury, CT) set at 50 Hz.  As controls, untransfected CHO cells and cells treated with 
the lipid alone were similarly processed.  The sonic extract was incubated with the 
cracking buffer (0.019 M Tris, 0.5% SDS, 0.35 M 2-mercaptoethanol, 7.5% glycerol, 
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0.05% bromophenol blue) for 3 min in a boiling water bath.  The particulate was 
sedimented by a 15-sec centrifugation at 6000 rpm, and the supernatant liquid from each 
sample was separated by electrophoresis in a 10% SDS-polyacrylamide gel.  The protein 
bands were electrophoretically transferred to a piece of nitrocellulose membrane, which 
was then blocked by incubation with 10% horse serum in PBS for 1 h at room 
temperature.  The membrane was processed for immunochemical staining as described 
above for dot immunobinding assay. 
Immunochemical staining of transfected CHO cells 
A 100-µl sample of each cell suspension was transferred to a microscope slide, let 
dry, and fixed with ice-cold acetone. The slide was next blocked with 10% nonfat dry 
milk for 1 h at room temperature with gentle rocking.  The cells were incubated at room 
temperature for 1 h with a rabbit anti-S. mutans cell wall diluted 1:200 in PBS.  The slide 
was next incubated with PBS containing 10 mM EDTA to inactivate endogenous alkaline 
phosphatase, as described by Dao (21), gently washed three times with PBS-T, then 
immediately incubated for 1 h with an alkaline phosphate-conjugated goat anti-rabbit 
immunoglobulin diluted 1:30,000 in PBS.  After incubation, the slide was washed three 
times with PBS-T and stained with a Fast Red RC solution prepared as described by 
Sigma.  After color development, the slide was rinsed three times with deionized water, 
observed on the light microscope, and photographed using an Olympus digital camera 
Model 3030Z (Olympus America Inc, Melville, NY). 
Differential immunogenicity of a DNA vaccine containing the S. mutans wall-
associated protein A gene versus that containing a truncated derivative antigen A 
lacking in the hydrophobic carboxyterminal terminal region  
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Animals 
Six-to-eight-week-old female Balb/c mice were purchased from the National 
Cancer Institute (Frederick, MD), and maintained in the controlled animal facilities of the 
University of South Florida Medical School.  All protocols using mice were approved by 
the Institutional Animal Care and Use Committee at the University of South Florida.  
The University program and facilities for animal care and use are fully accredited by the 
Association for Assessment and Accreditation of Laboratory Animal Care International 
(AAALAC). 
Bacterial strains and cell line 
E. coli TOP10 cell (Invitrogen, Carlsbad, CA) clones harboring  pcDNA-wapA or 
pcDNA-agA  were prepared in a previous study as described above.  The recombinant E. 
coli strain BL21 (DE3) transformed with the expression plasmid pGEX 6.1 Glutathione 
S-Transferase (GST), containing wapA or agA gene and expressing WapA or AgA as a 
GST fusion protein, were prepared previously and used in the present study as a source of 
recombinant antigens.  HeLa cells were obtained from American Type Culture Collection 
(ATCC) (Manassas, VA) for use in in vitro transfection experiments. 
DNA Vaccine 
The eukaryotic expression vector pcDNA3.1/V5-His-TOPO (Invitrogen, 
Carlsbad, CA) containing the full length wapA gene (previously wapA-E) or truncated 
agA gene (previously wapA-G), encoding WapA and AgA, respectively,  were cloned 
into the E.coli TOP 10 in a previous study and are referred to in the present report as 
pcDNA-wapA and pcDNA-agA vaccine, respectively.   
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Transfection of pcDNA-wapA in HeLa cells 
To determine the optimal transfection conditions, HeLa cells were transfected 
with pcDNA3.1/V5-His-TOPO containing the β-galactosidase gene (pcDNA-β-gal) 
mixed with the cationic lipid DMRIE-C at various ratios.  Briefly, HeLa cell cultures 
were seeded with 5 x 104 cells in a 24-well microtiter plate and grown overnight at 37 °C 
in a CO2 incubator until approximately 80% confluence.  The cells were washed in a 
serum-free medium and incubated with a transfection solution consisting of 2 µg of 
pcDNA-β-gal mixed with 2-24 µg of DMRIE-C in a serum-free medium.  After 4 h of 
incubation, a growth medium containing 20% fetal bovine serum (FBS) was added, and 
the incubation was continued for another 24 h.  On the following day, the cells were 
solubilized with M-PER Mammalian Protein Extraction Reagent (Pierce, Rockford, IL), 
and centrifuged, and the cell suspension was collected for β-galactosidase assay.  50 µl of 
cell lysate was added into the 96-well plate, mixed with 50 µl of 2X Assay Buffer 
(Promega, Madison, WI) that contained the substrate ONPG (O-nitrophenyl-β-D-
galactopyranoside).  β-galactosidase activity was measured at 420 nm with a 
spectrophotometer..    
Immunization of mice by the intranasal inhalation technique 
To investigate the diffusion of 100 µl of vaccine solution when administered by 
the intra-nasal drop technique, 100µl of sterile PBS containing 1/10 volume India ink 
were delivered slowly as droplets at the opening of the nostrils of the non-anaesthetized 
mouse held tightly by hand.  Hand pressure was applied to the lower mandible of the 
mouse in order to reduce swallowing of the instilled material during administration.  This 
procedure was performed on four mice, which were then sacrificed immediately and 30 
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min later. The mice tissues including nasal and oral cavities, lung tissue, esophagus, and 
trachea were inspected for any trace of the India ink as an indicator of vaccine diffusion. 
Immunization of mice 
Female BALB/c mice were distributed into five groups of three each and were 
immunized intra-nasally with one of the following:  50 µg pcDNA-wapA (Group 1) or 
pcDNA-agA (Group 2) combined with 150 µg of the cationic liposome carrier DMRIE-C 
(1:3, w/w).  The negative control mice were not immunized (Group 3) or administered 
with empty plasmid vector mixed with DMRIE-C at the same ratio (Group 4), or with 
PBS mixed with DMRIE-C (Group 5).  Two doses were administered at three-week 
intervals. 
Collection of saliva and blood samples 
Saliva and blood samples were collected prior to immunization, and 3 and 6 
weeks after boost immunization.  Briefly, saliva samples were collected after intra-
peritoneal injection of 100 µl of 1 mg/ml pilocarpine (Sigma, St. Louis, MO) in PBS to 
stimulate saliva secretion.  Saliva was immediately centrifuged at 735 g for 30 min.  The 
supernatant was collected, the protease inhibitor Phenylmethyl sulfonyl fluoride (PMSF, 
100 mM) was added at 1% (v/v), and the sample was stored at –20 °C until use.  Blood 
was collected from the tail vein, allowed to clot at room temperature for 1 h and stored 30 
min at 4 °C.  Serum was then separated from the clot by centrifugation at 3,210 g for 30 
min and stored at –20 °C.   Saliva samples from the mice in each group were pooled for 
analysis.  Serum samples were collected and tested individually. 
Dot immunobinding assay  
To investigate the presence of specific IgA in the saliva of the immunized mice, a 
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piece of 96 well-embossed nitrocellulose membrane was dotted with 10 µl per dot of 5 
µg/ml of purified GST-AgA fusion protein and allowed to dry at room temperature.  
After 10 min of incubation in the cold, the filter was blocked by incubation with PBS 
containing 2% Tween 20, at room temperature for 1 h.  Next, small NTC pieces 
containing antigen dots were cut out and incubated individually overnight at 4 °C with 
the diluted (1:2) saliva samples to be tested.  The pieces of NTC were washed six times 
with in PBS-T, and then incubated for 1 h with a HRP-conjugated goat anti-mouse IgA 
diluted to 1:10,000.  After a final wash in PBS-T, the membrane was incubated with a 
HRP chemiluminescent substrate (obtained from Amersham Pharmacia Biotech, 
Piscataway, NJ) for 1 min and exposed to an X-ray film (Kodak) for development. 
Enzyme linked immunosorbent assay (ELISA) 
Saliva and serum samples were assayed for anti-WapA salivary sIgA and serum 
IgG using enzyme-linked immunosorbent assay (ELISA).  The purified GST-AgA fusion 
protein was used as the coating antigen (146).  Immunolon IV 96-well microtiter plates 
(Dynex, Chantilly, VA) were coated overnight at 4 °C with 100 µl per well of 5 µg/ml 
solution of antigen in coating buffer (50 mM carbonate/bicarbonate buffer, pH 9.6).  The 
wells were blocked with 200 µl of 10% skim milk in PBS for 1 h and washed four times 
with PBS containing 0.05% Tween 20 (PBS-T).  Saliva was diluted 1:2 and serum at 1:16 
in PBS, each sample was added in serial 2-fold dilution to the wells, and the plate was 
incubated at 4 °C overnight.  After three washes with PBS-T, 100 µl of horseradish 
peroxidase (HRP)-conjugated goat anti-mouse IgA diluted to 1:1,000 in PBS-T was used. 
The plates were incubated for 1 h at room temperature.  Following extensive washes in 
PBS-T, 100 µl of QuantaBlue Fluorogenic peroxidase substrate (Pierce, Rockford, IL) 
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was added to each well and incubated for 30 minutes at room temperature.  Peroxidase 
activity was detected on the fluorometer by reading the excitation and emission at 325 nm 
and 420 nm, respectively.  The end point titers antigen-specific IgG and IgA were 
determined in triplicate and expressed as the reciprocal of the highest dilution giving an 
OD corresponding to 3 X the standard deviation above the mean of the background 
control sample.                                                 
Assay of antibodies to recombinant AgA                                                                                      
Pooled saliva from each group of mice was extensively absorbed with E. coli BL 
21 homogenate immobilized on nitrocellulose in order to remove unwanted antibodies.  
The E. coli recombinant clone expressing AgA and the negative control E. coli 
transformed with the vector pGEX-6P-1 alone were sonicated and centrifuged at 12,000 x 
g for 30 min.  The soluble fraction was loaded in triplicate lanes (2 µg/line) and separated 
by SDS-PAGE followed by electro-transfer of the protein bands onto a piece of 
nitrocellulose.  The protein bands were incubated with purified anti-WapA or –AgA 
antibodies and subsequent steps were as described previously for the dot immunobinding 
assay. 
Assay of antibodies to S. mutans WapA 
Cultures of S. mutans were grown in BHI supplemented with 2% sucrose for 16 h 
at 37 °C.  Cultures were sonicated and an equal volume of sonic extract was loaded in 4 
sets of duplicate lanes (2 µg/lane).  SDS-PAGE separated protein bands were transferred 
to 0.2 µm nitrocellulose membrane at 100V for 1 h.  Differential immunoreactivity of 
anti-WapA or –AgA antibodies to WapA was tested by incubating the membranes with 
each antiserum and following steps for the Western blot analysis as described above. 
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In vitro Adherence inhibition assay 
The influence of salivary IgA on the sucrose-dependent adherence of S. mutans 
GS-5 was assayed in vitro and quantified as described by Olson et al. (94) with some 
modifications.  At 6 weeks post-booster immunization, saliva samples collected from 
immunized or control mice, and the antigen-specific sIgA level was measured using 
ELISA.  Saliva samples with equivalent levels of specific sIgA were sterilized by mixing 
with 1/10 volume of chloroform and the aqueous layer, separated by centrifugation for 2 
min at 16,000 g, was diluted to 1:2 in PBS.  200 µl of saliva diluted in PBS was added 
into 24 well cell culture plates containing 200 µl of BHI medium prepared at two times 
the standard concentration and supplemented with 2% filter-sterilized (Millipore Corp.; 
0.45 µm pore size) sucrose. 
A saturated overnight culture of S. mutans was diluted to 1:100 in BHI medium 
and 10 µl of the diluted suspension was added into each well.  Binding assay was carried 
out by incubation of the plate at 37 °C for 20 h.  Saliva samples from pre-immunized or 
non-immunized mice were used as controls, and assayed as described above for the test 
samples.  After incubation, non-adherent S. mutans were removed by aspiration of the 
medium, and the wells were washed three times with 0.5 ml of 0.9% saline.  The washes 
were pooled. 
For quantitative analysis, the bacteria were detached from the wells by washing 
four times with 0.5 ml volumes of 0.5 N NaOH, and the washes were pooled.   S. mutans 
were collected from the washes by centrifugation at 6,000 g for 1 min, the supernatant 
was discarded, and the cell pellet was resuspended with 400 µl of 0.5 N sodium 
hydroxide.  The optical density (OD) of the suspensions was measured at a wavelength of 
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540 nm and the mean adherence level was determined and expressed as percent OD of 
the total cells (non-adherent cells in the culture medium plus adherent cells detached 
from the well by NaOH). 
Dextran binding Assay 
Dextran-binding properties were investigated for GST-WapA or GST-AgA fusion 
proteins using a Biotin-conjugated dextran (Sigma, St. Louis, MO) by dot 
immunobinding assay as follows.  GST-WapA and GST-AgA fusion proteins were 
obtained from the corresponding recombinant E. coli BL 21 after induction with IPTG 
and the recombinant proteins purified by chromatopgraphy on a glutathione-conjugated 
Sepharose column following the manufacturer protocol (Amersham, Piscataway, NJ).  
Next, 10 µl of 5 µg/ml of the purified protein was dotted onto a piece of 96 well-
embossed nitrocellulose membrane and processed as described above for the dot 
immunobinding assay.  The membrane was incubated with biotin-conjugated dextran for 
1 h at room temperature, and the dextran-binding protein was identified by incubation 
with AP-Streptavidin solution at room temperature for one hour, followed by in situ 
staining of AP activity (21).    
Statistical analysis 
Data for serum or saliva antibody titers were logarithmically transformed and 
statistical differences were determined by using the nonparametric Mann–Whitney U-test.  
Data obtained from the adherence inhibition assay were also analyzed with the 
nonparametric Mann–Whitney U-test for the difference in the median values among the 
groups. 
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Efficacy of DNA versus Protein Vaccine: Relative induction of mucosal IgA 
response to S. mutans Wall Associated Protein A 
Experimental animals 
Balb/c female mice, 6-8 weeks old, were purchased from Charles River 
Laboratories (Wilmington, MA) and were maintained in the animal facilities of the USF 
medical school.  
Cell lines  
HeLa cells were purchased from ATCC (Manassas, VA) and maintained in 
Dulbecco-modified Eagle medium supplemented with 10% fetal calf serum at 37 °C in 
5% CO2. 
Bacterial strains, plasmids, and media 
The three clones needed for this study were obtained previously and included the 
following:  Clone 1 consisted of recombinant E. coli TOP10 clone containing the wapA 
gene cloned into the mammalian expression vector pcDNA3.1/V5/His-TOPO.  The 
clones were used to propagate the plasmid containing wapA-pDNA.  The DNA plasmid, 
namely pcDNA-wapA which encodes the S. mutans WapA, was described previously.  
Clones 2 and 3 consisted of recombinant E. coli BL21 containing the wapA gene or agA 
gene cloned into the prokaryotic high expression fusion vector pGEX 6-1 GST.  These 
clones, designated BL21-WapA and BL21-AgA, expressed the WapA and AgA, 
respectively, as a fusion protein with GST.  The WapA or AgA expression plasmid, 
designated GST-WapA or –AgA, respectively, was also described previously.   
Cloning of murine IL-5 cytokine gene into the mammalian expression vector 
To investigate the effect of IL-5 on salivary IgA production in the immunized 
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mice, recombinant E. coli HB101 containing IL-5 cDNA cloned into vector pBR322 was 
obtained from ATCC.   PCR amplification was performed using primers for IL-5, which 
was designed based on the IL-5 DNA sequence found in Genebank (Accession No.   
NM_010558).  The primers used were as follows: Forward, 5′-ACC ATG AGA AGG 
ATG CTT CTG CAC-3′ and Reverse, 5′-TCA GCC TTC CAT TGC CCA-3′   The 
resulting fragment of 402 bp was cloned downstream of the CMV promoter into 
pcDNA3.1 vector.  PCR and cloning protocols used were described previously. 
Cloning of the cholera toxin B-subunit (ctb) gene into the mammalian expression vector 
The ctb plasmid construct was prepared by cloning a ctb gene into the mammalian 
expression vector pcDNA3.1/V5/His-TOPO according to the protocol above.  Genomic 
DNA of Vibrio cholera was obtained from ATCC.  Since the ctb gene sequence was 
known (GenBank accession no. D30053), the genomic DNA obtained was used as a 
template for the amplication of the CTB gene by PCR using specific primers.  The 
primers used were; Forward, 5′-ACC ATG ACA CCT CAA AAT ATT ACT GAT T-3′ 
and Reverse, 5′-TTA ATT TGC CAT ACT AAT TGC GG-3′.
Cloning of the ctb gene into a pGEX expression vector 
The ctb gene was cloned into prokaryotic high expression pGEX-6P-1 glutathione 
S-transferase (GST) fusion vector using the manufacturer protocol (Pharmacia).  PCR 
primers derived from the ctb gene sequence in GenBank (accession no. D30053) was 
used to amplify the ctb gene without signal peptide and was subcloned into the TA 
cloning vector pCR2.1-TOPO (Fig. 6) The ctb gene digested with EcoRI was ligated in 
frame with GST-tag into the pGEX GST fusion vector (Fig. 7).  The E. coli BL21 
competent cells were transformed with the ligation mixtures, the transformant containing 
 pGEX-ctb was grown at 37 °C, and expression was induced with 1mM IPTG as 
described previously.  After induction, cells were lysed by sonication and were purified 
by the Glutathione Sepharose 4B protocol.  The purity and identity of the protein was 
confirmed by 10% SDS-PAGE followed by Western blot analysis.  
 
 
FIG. 6.  Map of pCR2.1-TOPO plasmid vector. ctb gene was cloned into pCR2.1-TOPO. 
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FIG. 7.  Map of prokaryotic expression vector pGEX-6p-1.  The pCR2.1-TOPO clone 
containing ctb gene was excised and subsequently cloned via the EcoR1 restriction 
enzyme site into pGEX-6p-1 plasmid from which proteins can be expressed as fusion 
proteins with glutathione S-transferase (GST). 
 
DNA sequencing 
After construction, the plasmids were sequenced to confirm the orientation and 
sequence.  Plasmids were purified to sequencing grade using the alkaline lysis method 
described below and Sequences were determined by DNA sequence analysis conducted 
at the DNA sequencing core facility of the H. Lee Moffitt Cancer Center & Research 
Institute (Tampa, FL).  The primer sets for sequencing were T7 forward primer: 5′-TAA 
TAC GAC TCA CTA TAG GG-3′ and BGH Reverse primer: 5′-TAG AAG GCA CAG 
TCG AGG-3′.  
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Expression and Purification of WapA and AgA from E. coli recombinant clones 
To obtain enough proteins for the immunization study and for the preparation of 
rabbit antibodies, isolation of these proteins was scaled up. Both WapA and AgA were 
obtained from the corresponding recombinant E. coli BL21 (DE3) clones.  The clones 
expressing GST-WapA and GST-AgA were cultured at 37 °C in an incubator shaker 
overnight in batches of 500 ml 2x YTA medium containing 100 µg/ml ampicillin.  The 
following day, the overnight culture was diluted 1:100 into fresh pre-warmed 2x YTA 
medium, and incubation was continued at 37 °C until the A600 reached about 1.  Induction 
of protein expression and preparation of the protein lysate was followed in the same 
manner as described above. 
The protein lysate was incubated on a rocker for 30 min at room temperature, 
after 0.5 ml of glutathione-linked Sepharose 4B (Pharmacia) in a 50% slurry was added.  
The mixture was transferred onto a chromatographic column, and washed by adding 50 
ml of PBS/1 mM PMSF.  The fusion protein was eluted by 10 mM reduced glutatione in 
five aliquots of 300 µl each.  Cleavage of GST tag was carried out by incubation with 
PreScission protease as described previously.  The quantity of the AgA was determined 
by OD reading at 280 nm.  1 OD280 equals 0.5 mg/ml, the formula based on the extinction 
coefficient of free GST.  The purity and solubility of the AgA was analyzed by SDS-
PAGE. 
The amount of recombinant proteins without GST tags was determined by the 
bincinchonic acid method using reagents and protocols obtained from Sigma.  Briefly, 
0.1 ml of the sample was mixed with 2 ml of protein determination reagent (1 part 
Copper sulfate pentahydrate 4% solution added to 50 parts of Bicinchonic acid solution).  
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The mixture was mixed by vortex followed by incubation at 37 °C for 30 min.  After 
cooling of the tube to room temperature, the absorbance was recorded at 562 nm, and the 
concentration of protein determined from a standard curve established with solutions of 
bovine serum albumin (20, 40, 60, 80, 100 µg/ml) assayed in parallel.   
Measurement of GST Activity by CDNB Assay 
Rapid enzymatic detection assay using the GST substrate 1-chloro-2,4-
dinitrobenzene (CDNB) was used to optimize conditions for expression or to quantify the 
level of expression of GST fusion protein.  High affinity between the GST and 1-chloro-
2,4-dinitrobenzene (CDNB) resulted in a CDNB-glutathione with a strong absorbance at 
340 nm.  When a sample containing a GST fusion protein was incubated in a CDNB 
assay solution containing CDNB and glutathione, the relative or absolute amount of GST 
fusion protein in the sample could be calculated by comparing a standard curve of 
A340/min versus fusion protein amount.  Briefly, the total volume of 1000 µl CDNB assay 
solution (100 mM CDNB, 100 mM reduced glutatione, 10X reaction buffer and distilled 
waterl) was mixed and transferred into two UV-transparent cuvettes with 500 ml volume 
each.   
The soluble (post-sonicate) fraction of the fusion protein or the GST-WapA 
purified soluble protein was added into the sample cuvette to be assayed.  To the other 
cuvette (blank cuvette), a volume of 1X reaction buffer in an amount equal to the sample 
was added.  Measurements were conducted at 340 nm in a UV spectrophotomer at one-
minute intervals for 5 minutes.  Blanking the spectrophotometer with the blank cuvette 
was done before each reading of the sample cuvette.  Recorded absorbance readings were 
used to calculate A340/min/ml values which could be used as a relative comparison of 
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GST fusion protein content between samples. 
Production of protein vaccines and DNA vaccines against S. mutans WapA and AgA 
The plasmid DNA containing wapA or agA gene and the corresponding 
recombinant WapA and AgA were isolated and an average yield was calculated as a 
function of culture volume for comparison. Plasmid DNA containing wapA or agA was 
prepared from E. coli TOP-10 by a modified alkaline lysis method using a Qiagen 
HiSpeedTM Plasmid Maxi Kit (Valencia, CA), as described previously.  The goal was to 
optimize the isolation of these antigens as recombinant proteins or as genes separately 
inserted into a eukaryotic expression plasmid vector, and to compare the yield between 
the two target antigens.  The purified recombinant protein and DNA vaccines were used 
in the immunization study. 
Immunogenicity of the fusion proteins 
Considering that fusion proteins can elicit a strong and specific antibody response 
to the target antigens, it is hypothesized that the presence of GST did not interfere with 
the immunogenicity of the target protein.  Indeed, the antigenicity of WapA-GST and 
AgA-GST was demonstrated by immunodot analysis using a rabbit antibody to the wild 
type WapA and AgA.  Considering the advantage of skipping the cleavage of GST from 
the fusion proteins in term of time and money, this step was omitted from our production 
of protein vaccines.  
Preparation of rabbit polyclonal antibody against WapA 
Rabbit polyclonal antibody against WapA was prepared for the identification and 
immunochemical analysis of WapA and AgA in the present study. Briefly, six 4 kg 
female albino rabbits from the New Zealand strains were immunized intramuscularly 
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with 100 µl of 1mg/ml of WapA mixed with TiterMax Gold (Sigma) adjuvant Freund 
complete adjuvant (v:v).  Booster injections were administered with WapA or AgA mixed 
with the TiterMax Gold adjuvant (v:v) at three-week intervals.   Blood was collected before 
immunization and one week after each booster injection. 
The serum was separated by centrifugation and decomplemented by heating at 55 oC 
in a water bath for 30 min.  The serum was sterilized by adding 1/10 vol of chloroform, 
mixing, and centrifugation to obtain the aqueous upper layer containing the antibody.  Dot 
immunobinding assay and ELISA were performed to test the serum for the presence of a 
specific IgG antibody, as described previously.  Larger volumes of blood were obtained 
when a dilution of the antibody at 1:500 in PBS gave a positive reaction in immunodot 
analysis.   
Absorption of anti-E. coli and anti-GST antibody from rabbit serum 
Nonspecific binding of the antiserum to WapA was removed by extensive 
absorption of serum against E. coli and GST.  Anti-E. coli absorption was completed as 
described previously.  For the absorption of anti-GST antibodies, Glutathione Sepharose 
4B attached with GST was packed onto a gravity-flow column.  Serum was loaded on a 
column and incubated for 1 h at room temperature.  Incubation was continued for 1 h at 4 
C, and the absorbed serum flow-through was collected.  Fractions were tested for 
antibody activity using dot immunobinding assay (Fig. 8). 
 
 
 
 
  
 
FIG. 8.  Absorption of immune serum.  To remove non-specific binding of antiserum to 
WapA, anti-E. coli and –GST activity was absorbed from serum against sonicated E. coli 
fraction and purified GST dotted on a nitrocellular membrane.  A1 (anti-WapA), A2 
(anti-GST) or A3 (anti-E. coli) shows its antibody activity reacting on purified GST-
WapA, GST, or E. coli fraction, respectively, before absorption.  B1, B2, and B3 are 
corresponding antibody activity after absorption.   
 
Purification of IgG antibody against WapA 
WapA or AgA specific antibodies from post-immune rabbit serum were purified 
using the Melon™ Gel IgG Purification Kit, by the procedure specified by the 
manufacturer.  Serum was diluted by 1:10 with melon gel purification buffer and loaded 
on a gravity-flow column.  The specific antibodies were eluted with Melon Gel 
Purification Buffer, and the absorbance of the antibody fractions were measured at 280 
nm.   
Induction of WapA in presence of sucrose 
Cultures of S. mutans were grown in BHI or BHI supplemented with 2% sucrose 
for 16 h at 37 °C.  Cultures were sonicated and an equal volume of sonic extract was 
loaded in 4 sets of duplicate lanes (2 µg/lane).  SDS-PAGE separated protein bands were 
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transferred to 0.2 µm nitrocellulose membrane at 100V for 1 h.  Expression of WapA in 
the presence of sucrose was evaluated by probing membranes with anti-WapA antibodies. 
Immunization protocols 
The mice were divided into 3 groups as follows: Group 1 mice were intra-nasally 
immunized with pcDNA-wapA alone, or with pcDNA-il-5 encoding IL-5 or with 
pcDNA-ctb encoding the cholera toxin B subunit (CTB). Group 2 mice were immunized 
with WapA and CTB. Group 3 mice were primed with pcDNA-wapA and boosted with 
WapA.  
Collection of saliva 
Mice were injected by i.p. 100 µl pilocarpin (1 mg/ml) to induce salivary flow.  
Saliva was collected by aspiration from the cheek pouch.  Phenyl methyl sulfonyl 
fluoride (PMSF) was added at 1mM as a protease inhibitor and the saliva was stored at -
70 °C until use, at which time the sample was centrifuged and the supernatant used in 
immunochemical assays.  
Immunodot analysis 
The presence of specific sIgA expressed in the saliva of immunized animals was 
detected by immunodot analysis of the in situ staining for alkaline phosphatase.  A purple 
coloration was indicative of the presence of salivary sIgA against WapA.  Saliva from 
unimmunized mice served as negative controls.   
Enzyme-linked immunosorbent assay 
To follow the production of specific salivary IgA over time, ELISA was used to 
determine the salivary IgA titre.  Production of salivary IgA (mean titer from 6 animals 
and standard deviation) was calculated and plotted as a function of time post-imunization. 
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RESULTS 
B cell epitope prediction of the WapA protein 
Identification of B cell epitopes on the WapA was made using different 
parameters for prediction of antigenic determinants, including hydrophilicity, 
accessibility and flexibility, experimental antigenic determinant data, and 
physicochemical properties of amino acids (Fig. 9).  Consensus epitopes were identified 
based on predicted epitopes and their frequency within different algorithms.  Table 1 
shows the consensus antigenic determinants in the WapA sequence, indicating 11 
strongly antigenic sites within AgA and 4 sites around the membrane-spanning domain.    
 
 
 
 
 
 
 
 
 
 
 
  
FIG. 9.  B cell epitope prediction by four algorithms; Hopp and Woods (A), Parker (B), 
Welling (C), and Kolaskar and Tongaonkar algorithm (D). Values greater than 0 are 
predicted antigenic sites and are likely to be exposed on the surface of a folded protein 
(A, B, and C).  Kolaskar and Tongaonkar algorithm (D) gives sites that ares potentially 
antigenic a value above 1.0. 
         52
          53
TABLE 1. Consensus antigenic determinants within the WapA sequence. 
n Start Position Sequence End Position
1 5 RKLLSLVSVLTILLGAFWVTKIVKA 29 
2 53 PSKAVNYWEPLSF 65 
3 71 FPDEVSI 77 
4 83 LTIKLPEQLQFTT 95 
5 119 GEVTVTF 125 
6 152 SIPGVVN 158 
7 161 YNNVAYSSYVKD 172 
8 175 ITPISPDVNKVGY 187 
9 192 NPGLIHWKVLI 202 
10 213 TLTDVVG 219 
11 222 QEIVKDSLVAARLQY 236 
12 284 NAIFISYTT 292 
13 401 TSKQVTK 407 
14 409 KAKFVLP 415 
15 420 QAGLLLTTVGLVIVAVAGVYF 440 
 
Detection of MHC class II binding regions 
The amino acid sequences of AgA and its larger precursor WapA were analyzed 
using virtual matrices algorithms by which binding values were compared with 51 sets of 
known MHC class II alleles.  MHC Class II binding specificity was shown as the 
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percentage of motif matches within the sets of 51 DRB alleles that cover more than 90% 
of MHC Class II molecules expressed on antigen presenting cells.  Analysis at a 3% 
threshold identified 6 more promiscuous binding regions in WapA, but not in AgA (Fig. 
10).  One of these regions, beginning at residue 400 (Fig.10), showed the highest 
promiscuous binding regions with over 90% promiscuousness for the predicted region of 
peptide against 51 known MHC II alleles. 
 
 
 
 
 
 
  
FIG. 10.  Detection of MHC-II promiscuous binding motifs in WapA.  Motifs associated 
with 51 MHC class II alleles (listed under the graph) were identified in the sequence of 
WapA using a MHC class II binding motif-matching algorithm.   Each peak represents 
percent of promiscuousness for the predicted region of peptide against 51 known MHC II 
alleles that cover more than 90% of MHC Class II molecules expressed on antigen 
presenting cells.  Six distinct regions beginning at residue 294, 300, 382, 388, 394, and 
400 were identified which were within the WapA and not AgA. 
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 Identification of N- or O-glycosylation sites in WapA sequence 
Asn-Xaa-Ser/Thr sequences were identified on WapA, and asparagines residues 
predicted to be N-glycosylated were determined based on the potential value calculated 
using the NetNGlyc server.  Six sites were predicted to be N-glycosylated with high 
specificity across the WapA sequence (Fig. 11).  The O-glycosylated sites were 
predominantly predicted to be in coil regions (Fig. 12).   
 
 
FIG. 11.  Prediction of N-glycosylation sites in WapA sequence.  The X-axis represents 
protein length from N- to C-terminal and the Y-axis the predicted N-glycosylation 
potential at that position.  Values above the threshold (horizontal line at 0.5) are predicted 
to be N-glycosylated. 
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FIG. 12.  Predicted O-glycosylation sites in WapA sequence.  The X-axis represents the 
WapA sequence position in the multiple alignments and the Y-axis the predicted O-
glycosylation potential at that position.  A position with a potential (vertical lines) 
crossing the threshold (dotted line) is regarded as O-glycosylated. 
 
Glycosylation of the anti-WapA DNA vaccine candidates 
The possibility of WapA or AgA glycosylation was considered in the process of 
selecting the anti-S. mutans DNA vaccine candidates.  Cloning of a series of truncations 
of the wapA gene at the N-terminal and C-terminal ends into the expression vector 
pGEX-6P-1 glutathione S-transferase (GST) fusion vector demonstrated that only 
constructs GST-WapA-D, -E, -F, and –G, showed a strong cross-reaction with the 
polyclonal WapA antibody raised in rabbit (146).  Detailed descriptions of those inserts 
are as follows: 
wapA-D: 1335 b.p. fragment of wapA missing the promoter 
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wapA-E: 1251 b.p. fragment of wapA missing the promoter and signal peptide 
wapA-F: 968 b.p. fragment of wapA missing the promoter and wall spanning region. 
wapA-G: 885 b.p. fragment of wapA missing promoter, signal peptide, and wall-
spanning region 
The truncated wapA-E and wapA-G were selected to prevent target proteins from 
being glycosylated in mammalian host cells for the source of DNA vaccine construction. 
The wapA-E and wapA-G were truncated versions of wapA, both lacking in signal 
peptide sequence, therefore preventing target proteins from being glycosylated in 
mammalian host cells.  In eukaryotic cells, proteins are synthesized in the cytoplasm or in 
the endoplasmic reticulum.  Protein glycosylation occurs in the RER, and RER-
synthesized proteins are distinguished from those synthesized in the cytoplasm by the 
presence of signal peptides (13-36 residues containing 7-13-residue hydrophobic core 
flanked by several relatively hydrophilic residues usually with one or more basic residues 
near the N-terminus).  Similarly, bacterial membrane proteins are also preceded by signal 
peptides such as in the case of WapA. 
To avoid glycosylation of WapA, wapA-E, and wapA-G were selected, which 
were truncated versions of the wapA gene that did not contain sequences encoding the S. 
mutans signal peptide.  Taken with the lack of a eukaryotic signal sequence in the cloning 
vector, this meant that it was not likely that nascent protein synthesized in the cytoplasm 
could be translocated to the RER for further elongation and glycosylation.  Despite a 
number of potential glycosylation sites with Thr and Ser residues in the wapA gene, 
glycosylation was successfully prevented and antigenicity was conserved.  
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Codon optimization 
The ability of the vacinee to produce the protein encoded by the DNA vaccine is 
often correlated with comparative codon usage between foreign and host genes.  Analysis 
of the S. mutans or WapA gene sequence showed the difference of the codon usage 
frequencies compared to those prevalent in the human genome (Fig. 13 and 14).  The 
pattern of usage difference in the wapA position revealed 19 low-usage codons for 
expression in mammalian systems (Fig. 15).  In order to improve the heterologous 
expression of wapA sequence in the mammalian system, the frequency of wapA and 
human codon usage was determined, and optimized codons were suggested in Table 2. 
 
 
 
 
 
 
 
 
 
 
 
  
 
FIG. 13.  Comparison of codon usage for each amino acid used by S. mutans and H. 
sapiens genes.  Mean difference of 26.7% was calculated between two species. S. mutans 
codon was colored red.  The black bar was used for H. sapiens codon usage. 
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FIG.  14.  Codon usage of wapA gene compared with the H. sapiens genes for each 
amino acid.  Mean difference of 24.89% was calculated between two species.  Codon 
fraction colored in red is wapA.  H. sapiens was shown as the black bar. 
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FIG. 15.  Analysis of codon usage pattern of wapA to the common codon usage of H. 
sapiens at each position of the gene.  Red bar indicates low usage codon with less than 
10% codon match to the codon usage of H. sapiens.  Grey bar shows less than 20% of 
codon usage match. 
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Amino   wapA    Frequency    Human codon     Optimized   Human codon frequency    
Acid    codons  wapA codon   Frequency       codon       of the optimized codon 
Ala     GCA     24           23                  
        GCC     0            40               GCC           40 
        GCG     6            11 
        GCT     71           26   
Arg     AGA     27           20 
        AGG     9            20 
        CGA     9            11 
        CGC     9            19 
        CGG     0            21               CGG           21 
        CGT     45           8 
Asn     AAC     28           54               AAC           54 
        AAT     72           46        
Asp     GAC     13           54               GAC           54 
        GAT     88           46 
Cys     TGC     0            55               TGC           55 
        TGT     0            45 
Gln     CAA     89           26                
        CAG     11           74               CAG           74 
Glu     GAA     13           58               GAA           58 
        GAG     88           42        
Gly     GGA     33           25 
        GGC     4            34               GGC           34      
        GGG     13           25 
        GGT     50           16 
His     CAC     33           59               CAC           59 
        CAT     67           41 
Ile     ATA     8            16 
        ATC     20           48               ATC           48 
        ATT     72           35 
Leu     CTA     6            7 
        CTC     3            20   
        CTG     3            40               CTG           40 
        CTT     16           13 
        TTA     35           7 
        TTG     35           13 
Lys     AAA     74           42 
        AAG     26           58               AAG           58 
Met     ATG     100          100              ATG           100 
Phe     TTC     29           55               TTC           55 
        TTT     71           45 
Pro     CCA     57           27 
        CCC     7            11 
        CCG     36           28               CCG           28 
        CCT     0            33 
Ser     AGC     8            24               AGC           24 
        AGT     28           15 
        TCA     20           15 
        TCC     10           22 
        TCG     3            6 
        TCT     33           18 
Thr     ACA     49           28 
        ACC     7            36               ACC           36 
        ACG     8            12 
        ACT     35           24 
Trp     TGG     100          100              TGG           100 
Tyr     TAC     13           57               TAC           57 
        TAT     88           43 
Val     GTA     26           11 
        GTC     18           24 
        GTG     6            47               GTG           47 
        GTT     50           18 
Table 2.  Codon optimization of wapA gene.  The codons and their frequency of 
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occurrence in the WapA gene are compared with the codon frequencies of the most 
common codon usage of the human gene.  The codon-optimized WapA gene represents 
the optimal codon for human codon usage. 
 
Comparative sequence analysis of the putative collagen binding domain in WapA 
 Blasting the deduced amino acid sequence of WapA against the NCBI Conserved 
Domain Database (CDD) revealed a significant hit (E = 9e-20) for the collagen binding 
domain (Fig. 16A).  Amino acids at position’ 150 to 286 of WapA were aligned 100% 
with pfam05737 consensus residues of the collagen binding domain (Fig. 16B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
FIG. 16.   Alignment of deduced amino acid sequences of WapA with conserved domain 
databases.  (A) Domain organization of S. mutans WapA.  Amino acids 150-286 (putative 
CBD of WapA) were aligned 100% with 134 consensus residues of collagen binding 
domain in NCBI Conserved Domain Database (CDD).  WapA signal peptide (S), 
proteolytic cleavage site (PC), cell wall domain containing LPSTG motif (W), and 
membrane-spanning domain (M) are indicated. The shaded region denotes the putative 
collagen binding domain (150-286) that was represented by CBD.  The region of the 
expressed recombinant protein (rCBD) used in this study is also shown.  (B) Sequence 
identity (E = 9e-20) to the collagen binding domain family was identified within the pfam 
database (pfam05737), where 33.8% identity in 134 amino acids overlap.   
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Structure analysis of putative collagen binding domain in WapA 
Results of a secondary structure prediction algorithm using the 3D-PSSM 
program suggested that the submitted portion of WapA was a collagen binding domain.  
Prediction of secondary structure and its probable function as a collagen binding domain 
was matched significantly with the polypeptide chain of the collagen binding domain of 
the Cna protein from S. aureus with over a 95% confident hit (E = 1.68e-08) (Fig. 17).  
The putative collagen binding domain also has a significant hit (E = 5.3e-22) with the 
collagen-binding domain of S. aureus, from the result of sequence searches against 
SCOPE, suggesting a common function and implying a probable common evolutionary 
origin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
FIG.17.  The predicted secondary structure for the putative collagen binding domain in 
WapA was generated using the 3D-PSSM program, and was aligned to the significant 
structural match (E = 1.68e-08) of the fold library.  The predicted secondary structure of 
the putative collagen binding domain in WapA shares structure motifs showing similar 
secondary structure topology with the assigned collagen binding domain of the Cna 
protein from S. aureus.  E is extended beta strand; C is coil; and H is alpha helix. 
 
Expression of recombinant collagen binding domain 
A WapA gene fragment encoding the predicted collagen-binding domain was 
expressed in E. coli BL21 clone, and denoted rCBD.  rCBD was purified and cleaved 
from glutathione S-transferase with the PreScission protease.  The purified protein 
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 representing the collagen binding domain of wapA was shown as a single band of 
approximately 29 kDa in SDS-PAGE (Fig. 18). 
 
 
FIG.  18. Expression and purification of recombinant collagen binding domain.  C-
terminal truncated wapA-G cloned into pGEX-6P-1 was expressed in E. coli BL21.  The 
resulting fusion proteins were purified on glutathione-Sepharose column followed by 
cleavage of the GST tag with PreScission protease.  The purity of rCBD was evaluated on 
10% SDS-PAGE gels stained with Coomassie blue.  All lanes showed column pool and 
subsequent column passages. 
 
Collagen Binding Properties of WapA 
Immunodot analysis was used to detect the collagen binding properties of WapA, 
which contained the putative collagen binding domain.  As shown in Fig. 19B, biotin- 
labeled rCBD was bound to native type I collagen, indicating the putative collagen 
binding domain.  BSA, serving as the negative control (19A), did not bind native type I 
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 collagen, confirming specificity.   
 
 
 
 
FIG. 19. Collagen binding Assay.  The collagen binding property was identified for the 
putative collagen binding domain in WapA by an adaptation of the dot immunobinding 
method, but using Biotin conjugated recombinant CBD protein in place of the primary 
antibody.  A: No binding was detected with BSA used as a negative control.  B: Binding 
of soluble native type I collagen to rCBD protein was observed. 
 
Quantitative analysis of collagen binding property of WapA 
The WapA protein was evaluated for its ability to bind soluble collagen 
immobilized onto a microtiter plate in a concentration-dependent manner.  The putative 
rCBD in WapA bound quantitatively to the immobilized collagen type I, whereas no 
significant concentration-dependent binding was observed to the BSA (Fig. 20). Relative 
binding was measured by monitoring absorbance at 405 nm following the alkaline 
phosphatase reaction.  Data points represent the means of OD405 nm values + standard 
deviation from 3 independent experiments.   
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FIG. 20.  Binding of recombinant putative CBD of WapA protein to native type I 
collagen used at different concentrations.  Wells coated with BSA were used as the 
negative control.  Serially diluted, biotin-labeled rCBD protein was added to the wells in 
a volume of 100 µl, and the bound protein was detected by AP-streptavidin by reading 
the absorbance of the reaction mixture at 405 nm.  Data are plotted as the mean values of 
three experiments.  
 
Cloning of truncated wapA genes into pcDNA3.1/V5/His-TOPO 
After transformation of E. coli Top 10 with the eukaryotic expression vector 
pcDNA3.1/V5/His-TOPO containing a truncated wapA gene, wapA-E or wapA-G, 
plasmid DNA was isolated from the recombinant clones and amplified by PCR using a 
forward primer specific to the T7 sequence of the vector upstream of the multicloning site 
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 and a reverse primer specific to the S. mutans gene insert. Analysis of the PCR products 
by agarose gel electrophoresis showed that both constructs contained a DNA insert of the 
correct size and in the correct orientation (Fig. 21).  The complete nucleotide sequence of 
these fragments was confirmed (Fig.22 and Fig. 23). 
 
 
FIG. 21.  Insertion of wapA-E and wapA-G fragments containing an initiation codon into 
the pcDNA3.1 eukaryotic expression vector. Confirmation of the correct orientation of 
the inserts.  The PCR amplification of wapA-E and wapA-G DNA with different 
combination of primers.  Lane 1, Molecular mass markers, Lanes 2 and 3, a forward T7 
primer specific to the sequence of the vector upstream of the cloning site with BGH 
reverse for downstream of the cloning site for each truncation; Lane 4, Forward wapA-E 
specific primer with BGH reverse primer; Lane 5, Forward wap-G primer with BGH 
reverse primer; Lane 6, a forward T7 primer with wapA-E specific reverse primer; Lane 
7, a forward T7 primer with wapA-G reverse primer; Lane 8, forward wapA-E primer 
with reverse wapA-E; Lane 9, forward wapA-G primer with reverse wapA-G. 
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   1 gagccaagct ggctagttaa gcttggtacc gagctcggat ccactagtcc 
  51 agtgtggtgg aattgccctt accatggacc aagtcacaaa ttatacaaat 
 101 acggcttcta tcacaaaatc agatggtaca gcactttcta atgatccatc 
 151 taaggctgtt aattattggg aaccactttc tttcagtaat tctattactt 
 201 tcccagatga agtcagtatt aaggctgggg atactttaac cattaagttg 
 251 ccagagcaat tacaatttac gactgctcta actttcgatg ttatgcatac 
 301 caatgggcaa ttagctggta aagcaacaac tgatcctaat acaggagaag 
 351 taacagttac ctttactgat atttttgaaa aactgcctaa tgataaggct 
 401 atgacattaa attttaatgc acaattgaat cataacaata tttctattcc 
 451 tggtgttgta aactttaact ataataatgt tgcttatagt tcttatgtta 
 501 aagacaaaga tattacgcca ataagtccag atgttaacaa agtgggttat 
 551 caggataaaa gtaatcctgg tttgattcac tggaaagttc tcatcaacaa 
 601 caaacaaggt gctattgata atttgacttt gactgatgtt gtcggagaag 
 651 atcaagaaat cgtaaaagat tccttggttg ctgcacgctt gcagtacatt 
 701 gctggtgatg atgttgacag tttagatgaa gctgcttcgc gaccttatgc 
 751 tgaggatttt tcaaaaaatg ttacttatca aactaatgat ttaggattga 
 801 caacaggatt tacctataca attccaggat ccagtaacaa cgctatcttt 
 851 atctcttata ctactcgttt aacttcttct caatctgctg gtaaagatgt 
 901 cagcaacact attgctattt caggaaataa tattaattat tccaatcaaa 
 951 caggctacgc tcgtattgaa tccgcatatg gtagagctag ttctagagta 
1001 aagaggcaag cagaaacaac aactgttact gaaacaacaa ctagtgaagc 
1051 gacaacagaa acaagtagta caacaaataa taattcaact actacagaaa 
1101 cagctactag cacaacagga gcttcaacaa cacaaacaaa aacgactgct 
1151 tctcaaacga atgttccgac aacaacaaac ataacaacaa cttcaaaaca 
1201 agtaaccaag caaaaagcga aatttgtttt accatcaaca ggtgaacaag 
1251 cagggctttt gttaactact gtaggtcttg taattgttgc tgtggcaggt 
1301 gtctatttct atagaacacg tcgttaaaag ggcaattctg cagatatcca 
1351 gcacagtggc ggccgctcga gtctagaggg cccgcggttc gaaggtaagc 
1401 ctatccctaa ccctctcctc ggtctcgatt ctacgcgtac cggtcatcat 
1451 caccatcacc attgagttta aaccc 
 
FIG. 22.  Nucleotide sequence of the recombinant wapA (wapA-E) cloned into a 
eukaryotic expression vector, pcDNA3.1.  The underlines indicate the regions used as 
primers for the amplification of the wapA.  The Kozak sequence, initial Met, and 
terminal codon are highlighted in yellow. 
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   1 gagccaagct ggctagttaa gcttggtacc gagctcggat ccactagtcc 
  51 agtgtggtgg aattgccctt accatggacc aagtcacaaa ttatacaaat 
 101 acggcttcta tcacaaaatc agatggtaca gcactttcta atgatccatc 
 151 taaggctgtt aattattggg aaccactttc tttcagtaat tctattactt 
 201 tcccagatga agtcagtatt aaggctgggg atactttaac cattaagttg 
 251 ccagagcaat tacaatttac gactgctcta actttcgatg ttatgcatac 
 301 caatgggcaa ttagctggta aagcaacaac tgatcctaat acaggagaag 
 351 taacagttac ctttactgat atttttgaaa aactgcctaa tgataaggct 
 401 atgacattaa attttaatgc acaattgaat cataacaata tttctattcc 
 451 tggtgttgta aactttaact ataataatgt tgcttatagt tcttatgtta 
 501 aagacaaaga tattacgcca ataagtccag atgttaacaa agtgggttat 
 551 caggataaaa gtaatcctgg tttgattcac tggaaagttc tcatcaacaa 
 601 caaacaaggt gctattgata atttgacttt gactgatgtt gtcggagaag 
 651 atcaagaaat cgtaaaagat tccttggttg ctgcacgctt gcagtacatt 
 701 gctggtgatg atgttgacag tttagatgaa gctgcttcgc gaccttatgc 
 751 tgaggatttt tcaaaaaatg ttacttatca aactaatgat ttaggattga 
 801 caacaggatt tacctataca attccaggat ccagtaacaa cgctatcttt 
 851 atctcttata ctactcgttt aacttcttct caatctgctg gtaaagatgt 
 901 cagcaacact attgctattt caggaaataa tattaattat tccaatcaaa
 951 caggctacta aaagggcaat tctgcagata tccagcacag tggcggccgc 
1001 tcgagtctag agggcccgcg gttcgaaggt aagcctatcc ctaaccctct 
1051 cctcggtctc gattctacgc gtaccggtca tcatcaccat caccattgag 
1101 tttaaaccc 
 
FIG. 23.  Nucleotide sequence of the recombinant agA (wapA-G) cloned into a 
eukaryotic expression vector, pcDNA3.1.  The underlines indicate the regions used as 
primers for the amplification of the agA.  Yellow highlight shows the Kozak sequence, 
initial Met, and terminal condon.   
 
Quality control of plasmid production for immunization 
The plasmid DNA production must include a good quality control process in 
order to assure the plasmid DNA, especially when used as a therapeutic agent including 
vaccination, is free of any contaminats, which include proteins, RNA, endotoxins, 
genomic DNA of the host cell, or any components used in the purification process.  
Purification of supercoiled plasmid without containing other isofoms such as nicked, 
linear, dimers or concatemers plasmids is an essential factor for quality control of 
 plasmid production, as well as function as a reproducible, scalable and economical 
purification process.  Plasmid isolation was performed using the Qiagen procedure 
approved to produce plasmid DNA for human clinical Phase I studies in the U.K. (14) 
and other European countries, as well as in the United States by the FDA (49). 
Supercoiled plasmid and any other isoforms were analyzed by running total 
plasmid DNA in 1% agarose gel electrophoresis (Fig. 24A).  Plasmid DNA identity and 
quality were accessed through restriction analysis by BstXI digest of the parental vector 
and wapA or agA DNA vaccine constructs (Fig. 24B).  DNA purity was assessed by 
using spectrophotometric analysis and calculation from its absorbance ratio of 
260nm/280nm. 
A.     B. 
 
FIG. 24.  Agarose gel electrophoresis and restriction enzyme digestion of pcDNA3.1-
wapA or pcDNA3.1-agA for assuring the quality of DNA vaccines.  A.  Lane 1, λ DNA-
Hind III Digest.  Lane 2, pcDNA3.1-wapA.  Lane 3, pcDNA3.1-agA.  Lane 4, pcDNA 
3.1 parental vector.  B.  Lane 1, 100 base pair ladder.  Lane 2, pcDNA3.1-agA-BstXI 
digest.  Lane 3, pcDNA3.1-wapA-BstXI digest. Lane 4, pcDNA3.1-BstXI digest. 
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 Expression of WapA and AgA by dot immunobinding assay 
The expression of wapA and agA genes was investigated by immunodot analysis 
of the sonic extract of transfected CHO cells against a rabbit antiserum to the S. mutans 
cell wall.  Chemiluminescence detection showed a high level of expression of both wapA 
and agA.  No reaction was obtained with the negative control CHO cells (Fig. 25). 
 
 
           A           B           C           D          E 
 
FIG. 25.  Immunodot analysis.  The sonic extracts were dotted onto a piece of 
nitrocellulose filter.  Expression was detected by chemiluminescence substrate ECL for 
HRP.  (A) A 4B2 clone sonic extract (positive control).  (B)  A wapA-E transfected CHO 
cell.  (C) A wapA-G transfected CHO cell.  (D) CHO cell treated with the lipid alone 
(negative control).  (E) Untransfected CHO cells (negative control). 
 
Western immunoblot analysis of WapA and AgA expressed in transfected CHO cells 
To determine the molecular size of the proteins expressed in transfected CHO 
cells, Western immunoblot analysis was performed on aliquots of the cell sonic extract. 
Proteins with the anticipated molecular weights of 52,000 and 29,000 were observed with 
the transfected CHO cell samples, but not with the negative control untransfected CHO 
cells (Fig. 26). 
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FIG. 26.  Western immunoblot analysis of wapA-E and wapA-G gene expression using 
rabbit antiserum to S. mutans cell wall antigens in CHO cells at 24 h post-transfection.  
Lane 1, WapA-E sonic extract.  Two bands of 52 and 29 kDa were obtained 
corresponding to WapA and AgA, respectively.  Lane 2, WapA-G sonic extract.  The 
anticipated 29-kDa band was obtained (smaller bands are probably attributable to 
proteolytic degradation).  Lane 3, CHO cell treated with the lipid alone as a negative 
control.  Lane 4, Untransfected CHO cells as a negative control. 
 
In situ immunochemical staining of transfected CHO cells 
To localize the WapA and AgA protein in transfectants, immunochemical staining 
was performed using a rabbit antiserum to S. mutans cell wall antigens followed by an 
alkaline phosphatase-conjugated goat antibody to rabbit immunoglobulins.  Detection 
         76
          77
was performed using the chromogenic substrate fast red stain. The presence of antigen 
was identified by a red coloration. The WapA protein was found mainly associated with 
the CHO cell membrane and budding vesicles, whereas AgA was found in transfected 
cells and extracellular surroundings (Fig. 27). Thus, the wapA and agA gene constructs 
were efficiently taken up by CHO cells through lipid-mediated transfection and expressed 
in these eukaryotic cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 A               B 
                  
       
  
C                          D  
FIG. 27.  In situ expression of WapA and AgA at 24 hours post-transfection. Transfected 
CHO cells were fixed on a slide with cold acetone, blocked with skim milk, and 
immunochemically stained with antibody to S. mutans cell wall.  Fast Red RC was used 
as a substrate for alkaline phosphatase.  (A) A CHO cell treated with the lipid alone as a 
negative control.  (B) Expression of AgA in transfected cells and extracellular medium.  
(C) Expression of WapA in transfected cells and budding vesicles.  (D) Expression of 
WapA in large vesicles.  (A, B and C were identified on the light microscope at X400 and 
photographed at X1000).  
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 Optimization of pcDNA-lipid complex  
HeLa cells were transiently transfected to determine the optimum ratio of 
pcDNA-lipid complex.  The highest transfection efficiency was obtained with 2 µg 
pcDNA and 10 µg DMRIE-C, the ratio corresponding approximately to the ratio in 
molarity of 1:2 of pcDNA and DMRIE-C.  Decreased β-galactosidase activity was 
indicative of cell death (Fig. 28). 
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FIG. 28. Optimization of DMRIE-C Reagent and pcDNA ratio for transfection.  In order 
to determine the optimal DMRIE-C formulation, different pcDNA3.1-βgal 
DNA:DMRIE-C lipid ratios were tested in Hela cells.  At 24 h post-transfection, cells 
were solubilizd and assayed for the β-galactosidase activity at 415 nm with a 
spectrophotometer.  Data are means and standard deviation of duplicates.  
 
Dot immunobinding assay                                                                                                  
Four weeks after the booster immunization, mice immunized with plasmid 
containing wapA or agA complexed with DMRIE-C showed the presence of anti- AgA 
salivary sIgA by immunodot analysis using a HRP-conjugated anti-mouse IgA and a 
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 chemiluminescence substrate for HRP (Fig. 29).  No reaction was detected in the saliva 
obtained from the control mice. 
 
 
FIG. 29.  Immunodot analysis of anti-WapA and AgA salivary IgA production.  Purified 
GST-AgA fusion protein was dotted onto a piece of nitrocellulose filter in line 2.  
Purified GST only was used as a control in line 1.  The filter was incubated overnight 
with the saliva (1:2 dilution in PBS) of mice that were immunized with (A) PBS, (B) 
DMRIE-C lipid, (C) pcDNA3.1 vector with DMRIE-C, (D) WapA DNA vaccine 
construct with DMRIE-C, and (E) AgA DNA vaccine construct with DMRIE-C. 
Chemiluminescence detection showed the presence of anti-WapA and AgA salivary IgA 
in 2D and 2E.  No reaction was obtained with the saliva of control mice. 
 
Humoral immune responses induced by DNA vaccines 
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To access the level of humoral immune response after DNA immunization, serum 
or saliva was collected from the control mice and the mice immunized with pcDNA-
wapA or pcDNA–agA at various time points after the second immunization.  ELISA of 
the saliva obtained showed a significantly higher level (P < 0.05) of antigen-specific IgA 
in the immunized mice as compared to the background level in the control group (Fig. 
 30A).  Similarly, the levels of antigen-specific IgG were observed in the serum of the 
immunized mice as compared to that of the control animals (P < 0.05) (Fig. 30B).  Both 
salivary IgA and serum IgG titers were higher in the samples collected from the pcDNA-
wapA immunized mice as compared to those immunized with pcDNA-agA vaccine (P < 
0.05)  (Fig. 30).  
 
 A.               B. 
 
FIG. 30.  Salivary IgA and serum IgG responses in mice.  Following intra nasal 
immunization with pcDNA-wapA or pcDNA-agA, pooled saliva (A) and serum (B) 
samples were analyzed by ELISA using plates coated with recombinant AgA.  Mice 
immunized with either pcDNA-wapA or pcDNA-agA showed a significantly higher 
signal than the background level (control mice), both in saliva and serum (P < 0.05).  
 
Western immunoblot analysis of antibody response against AgA 
Analysis of the saliva of the mice immunized with pcDNA-agA or with pcDNA-
wapA by Western immunoblot showed the presence of sIgA binding to the GST-WapA 
antigen band of approximately 58 kDa (Fig. 31). 
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FIG. 31. Western immunoblot analysis of salivary sIgA Abs to wapA and agA DNA 
vaccines.  The results showed the anticipated antigen bands (GST-AgA fusion protein of 
approximately 58 kDa) with the saliva of mice immunized with agA-pDNA (Lane 3) or 
with wapA-pDNA (Lane 5).  No band was obtained with either mouse saliva against the 
extract of the control E. coli harboring empty vector (lanes 4 and 6).  As anticipated, no 
band was obtained with the saliva of the control mice (Lane 1 and 2). 
 
Induction of S. mutans WapA  
The WapA is involved in sucrose-dependent adherence and aggregation (101).  In 
order to determine whether sucrose induces further the expression of WapA, S. mutans, 
Western blot analysis was performed on sonic extracts of each culture grown with or 
without sucrose presence.  Expression of S. mutans WapA was strongly enhanced in 
presence of 2% sucrose, suggesting WapA expression is regulated by sucrose (Fig. 32).  
  
 
FIG. 32.  Expression of WapA in presence of sucrose.  Enhanced WapA expression was 
shown in the S. mutans culture grown in presence of 2% sucrose. 
 
Western immunoblot analysis of antibody response against WapA 
Reactivity against WapA was higher with the anti-WapA antibody than with the 
reactivity of the anti-AgA, suggesting a stronger reaction is attributable to the additional 
epitopes seen in WapA but not in AgA (Fig. 33). 
 
 
FIG. 33.  Western blot analysis of S. mutans WapA using polyclonal antiserum raised 
against AgA or WapA.  Stronger immunoreactivity was shown with anti-WapA serum 
that that of anti-AgA. 
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Sucrose-dependent adherence inhibition assay 
Saliva of the immunized mice, with pcDNA-wapA or pcDNA-agA, was evaluated 
for the ability to inhibit the S. mutans in vitro sucrose-dependent adherence.  A 
significantly higher inhibition of adherence (P<0.05) was obtained with the saliva of the 
mice immunized with pcDNA-wapA (21% inhibition) as compared to the Saliva of the 
mice immunized with pcDNA-agA (7% inhibition) shown in Table 3.  
 
TABLE 3.  EFFECT OF SALIVARY IgA PRODUCED IN RESPONSE TO 
IMMUNIZATION ON BACTERIAL ADHERENCE 
                             Immunization 
Group                  Treatment a                                 Mean % adherent cells/total cells + SD b
   A                       pcDNA Vector only ……………………………………… 61.11 + 1.75 
   B                       pcDNA-wapA……………………………………………   48.53 + 1.36 
   C                       pcDNA-agA………………………………………………  57.00 + 1.44 
a Saliva collected was diluted 1:2 in PBS and added to triplicate S. mutans culture wells.    
b Significant inhibition (P<0.05) of S. mutans in vitro sucrose-dependent adherence was 
observed with the saliva of mice immunized with pcDNA-wapA (B), and to a lesser 
extent with the saliva of mice immunized with pcDNA-agA (C) or with  pcDNA vector 
alone (A)  
 
Dextran-binding properties 
Analysis of recombinant WapA or AgA for the ability to bind biotin-labeled 
dextran showed that WapA bound dextran, but AgA did not.  As anticipated, no dextran-
binding activity was observed with GST used as a negative control (Fig. 34).  
 
 
  
 
    
 
                
FIG. 34. Dextran-binding assay.  The dextran-binding property was identified on GST 
fusion proteins containing WapA or AgA against the Biotin-dextran conjugate using the 
Dot immunobinding method.  The WapA showed a capacity to bind dextran (1), but the 
AgA did not (2).  GST only was dotted as a control (3).  
 
Cloning and sequencing of il-5 and ctb recombinant genes 
The orientation and identity of the il-5 cDNA and ctb gene clones were confirmed 
by the nucleotide sequencing (Fig. 35). The cloned il-5 cDNA was 402 bp of ORF 
without signal peptide, and it encoded 133 amino acid residues.  The sequencing of the 
ctb clone showed correct identity of the ctb gene insert including 312 nucleotides 
encoding 103 amino acids.  
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A.   
 
TTAAGCTTGGTACCGAGCTCGGATCCACTAGTCCAGTGTGGTGGAATTGCCCTTACCATGAGAAGGATGCT
TCTGCACTTGAGTGTTCTGACTCTCAGCTGTGTCTGGGCCACTGCCATGGAGATTCCCATGAGCACAGTGG
TGAAAGAGACCTTGACACAGCTGTCCGCTCACCGAGCTCTGTTGACAAGCAATGAGACGATGAGGCTTCCT
GTCCCTACTCATAAAAATCACCAGCTATGCATTGGAGAAATCTTTCAGGGGCTAGACATACTGAAGAATCA
AACTGTCCGTGGGGGTACTGTGGAAATGCTATTCCAAAACCTGTCATTAATAAAGAAATACATTGACCGCC
AAAAAGAGAAGTGTGGCGAGGAGAGACGGAGGACGAGGCAGTTCCTGGATTACCTGCAAGAGTTCCTTGGT
GTGATGAGTACAGAGTGGGCAATGGAAGGCTGAAAGGGCAATTCTGCAGATATCCAGCACAGTGGCGGCCG
CTCGAGTCTAGAGGGCCCGCGGTTCGAAGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGC
GTACCGGTCATCATCACCATCACCATT 
 
B.  
 
TTAAGCTTGGTACCGAGCTCGGATCCACTAGTCCAGTGTGGTGGAATTGCCCTTACCATGACACCTCAAAA
TATTACTGATTTGTGTGCAGAATACCACAACACACAAATATATACGCTAAATGATAAGATATTTTCGTATA
CAGAATCTCTAGCTGGAAAAAGAGAGATGGCTATCATTACTTTTAAGAATGGTGCAATTTTTCAAGTAGAA
GTACCAGGTAGTCAACATATAGATTCACAAAAAAAAGCGATTGAAAGGATGAAGGATACCCTGAGGATTGC
ATATCTTACTGAAGCTAAAGTCGAAAAGTTATGTGTATGGAATAATAAAACGCCTCATGCGATTGCCGCAA
TTAGTATGGCAAATTAAAAGGGCAATTCTGCAGATATCCAGCACAGTGGCGGCCGCTCGAGTCTAGAGGGC
CCGCGGTTCGAAGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGCGTACCGGTCATCATCA
CCATCACCATT 
 
FIG. 35. Nucleotide sequence of il-5 or ctb gene insert.  The il-5 cDNA or ctb gene 
subunit was cloned into the pcDNA3.1 mammalian expression vector and sequenced. The 
coding regions, including the ATG start codon, are in red, and the Kozak sequence is 
underlined.  The primers used are indicated in blue. 
 
Western immunoblot analysis of the purified GST-CTB fusion protein 
The purified GST-CTB fusion protein was confirmed by the Western immunoblot 
with monoclonal antibody to Ctb.  The 40-kDa band was identified on the nitrocellulose 
lines containing purified GST-CTB fusion protein or lysate of E. coli containing the 
construct.  No band was shown on the line with purified GST (Fig. 36). 
 
 
  
 
FIG. 36. Western immunoblot analysis of purified GST-CTB fusion protein.  Specific 
binding of the anti-CTB monoclonal antibody to the cloned and purified GST-CTB 
protein (Line 2). No immunoreactivity was shown to the purified GST protein (Line 3). 
The molecular masses standards (lane 1) are indicated (in kilodaltons) on the left of the 
blot. 
 
Expression of recombinant WapA or AgA 
WapA and AgA are expressed as GST-fusion poteins in the E. coli recombinant 
clones WapAE and WapA-G, respectively.  Expression of both antigens was observed 
(Fig. 37 and Fig. 38).  
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FIG. 37.  SDS-PAGE analysis of the GST-wapA fusion protein expression.  A highly 
expressed truncated wapA-G gene as GST fusion was used as the coating antigen in an 
ELISA assay.  Lane 1, E. coli BL 21 lysate.  Lane 2, a soluble sonic extract containing 
GST-wapA-G.  Lane 3, GST-wapA-G protein purified from the soluble fraction.  Lane 4, 
M.W. marker. 
 
 
Fig. 38.  Expression of wapA and agA genes as GST fusions.  SDS-PAGE of purified 29 
kDa GST (lane 1), 81 kDa GST-WapA (lane 2), and 58 kDa GST-AgA (lane 3) are 
shown on coomassie blue stained gel.  Molecular weight standards were run in lane 1.  
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Production of DNA vaccine 
The recombinant E. coli TOP10 containing the target DNA was cultured in an LB 
medium containing ampicillin added at 50 micrograms per milliliter, and plasmid DNA 
was isolated by the modified alkaline lysis method using a kit from Qiagen (HiSpeed 
Maxi Kit), Valencia, CA.  The average yield of plasmid DNA containing the wapA gene 
(pcDNA-wapA) was 2 mg/L E. coli culture, whereas that of the plasmid containing the 
agA gene (pcDNA-agA) was only 0.92 mg/L.  One reason for the low yield of pcDNA-
agA is the tendency of the recombinant E. coli to lyse.  In order to improve the yield of 
pcDNA-agA, the antibiotic chloramphenicol was added to the culture. As a result, the 
yield of plasmid copies was improved by approximately 2.5 fold (2.3 mg/L E. coli 
culture).  Hence, we have established the conditions for the obtaining of comparable 
levels of production of pcDNA-wapA and pcDNA-agA. 
Production of Protein vaccine 
The proteins WapA and AgA were obtained separately, each as a fusion protein 
with the enzyme glutathione S-transferase (GST), respectively designated as WapA-GST 
and AgA-GST.  The yield of these proteins was determined by optical density readings at 
280nm, and calculated based on the extinction coefficient of GST (1 OD280 = 0.5 mg 
protein/ml).  The fusion proteins were purified by affinity column chromatography on 
GST-Sepharose (Promega, Madison WI) and purity was demonstrated by SDS-PAGE, 
where a single protein band was obtained for each GST-fusion protein.  Originally, the 
yield of AgA-GST and WapA-GST was 2.5 mg/L and 1.2 mg/L, respectively.  One 
reason for the lower yield of WapA-GST was due to the insolubility of WapA, since this 
protein contains an extra hydrophobic membrane-binding region at the C-terminal end as 
 compared to AgA.  Sarkosyl was used to solubilize the E. coli membrane and improve 
the recovery of WapA-GST.  The results showed a two-fold increase up to 2 mg/L.   
Immunodot analysis 
The presence of anti-WapA salivary IgA was detected by Immunodot analsis.  
Weak staining was shown in the saliva from the DNA vaccine immunized mice while a 
much stronger reaction was obtained with the protein vaccinated mice (Fig. 39).  No 
reaction was detected from the saliva of the negative control or that of the DNA vaccine 
alone without cationic lipid. 
  
 
FIG. 39.  Immunodot analysis.  Saliva from immunized mice were tested for 
immunogenicity of specific S-IgA against WapA.  Group 1 mice immunized with 
pcDNA-wapA alone (2), or with pcDNA-il-5 (3) or pcDNA-ctb (4) showed weak 
immunogenicity to WapA.  Group 2 mice immunized with AgA (6) or WapA (7) showed 
strong reaction to WapA.  Group 3 mice that is primed with pcDNA-wapA and boosted 
with WapA protein (5) revealed strong immunogenicity to WapA.  No immunogenicity 
was shown for non-immunized (1) or WapA DNA vaccine only without adjuvant (8). 
 
Immunomodulatory effect on humoral immunity 
To investigate the influence of il-5 or ctb co-immunization on the level and 
duration of salivary IgA response, saliva from the control and immunized mice with or 
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without the adjuvant was analyzed using an ELISA assay.  Co-immunization with 
pcDNA-il-5 resulted in a significant (P < 0.05) but temporal sIgA response after boosting 
with a third injection of DNA as compared to that of the control mice group (Fig. 40A).  
This was followed by a drop in the level of sIgA with the additional booster, indicating 
that the booster effect was aborted and, therefore, no memory immune response was 
elicited.  The level of sIgA antibody induced by pcDNA-ctb as an adjuvant was improved 
more rapidly and consistently as compared to that of the control or pcDNA-il-5 co-
immunization (Fig. 40A).  
Mice primed with pcDNA-wapA followed by the WapA boost produced sIgA 
levels comparable to mice receiving 2 WapA doses (Fig. 40B).  The antigen-specific 
antibody was not affected in the groups administered with DNA only without adjuvant 
and the non-immunized group (Fig. 40). 
 
 
 
 
 
 
 
 
 
 
 
  
A.  
                   
B.  
 
FIG. 40.  WapA-specific sIgA antibody response in the saliva of mice immunized with 
DNA or protein vaccine.  Levels of the antigen-specific S-IgA was determined in the 
saliva of immunized mice given pcDNA-wapA alone, or with pcDNA-il-5 or pcDNA-ctb 
(A) or primed with pcDNA-wapA and boosted with WapA or WapA and CTB (B) by the 
i.n route.  Each vaccine was injected biweekly, as shown by black arrows, for a total of 
four inoculations.  Each point is the mean of triplicate values. 
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DISCUSSION 
 
Dental caries is a significant health problem in humans and treatment is costly due 
to the high prevalence in the population.  Despite longstanding effort at the development 
of a caries vaccine, an efficacious vaccine protocol has not yet been developed.  The 
establishment of an effective mucosal vaccine would be an exceptionally significant 
accomplishment that would greatly enhance the ability to provide preventive vaccination 
for this disease.  This is especially true for the groups at risk such as underserved 
communities which do not have access to water fluoridation and periodical preventive 
dental care, and children and adults with medical problems or receiving medical 
treatments that reduce salivary flow.  Once developed, the dental vaccine should also 
serve as a model for the preparation of similar vaccines against other infectious agents, 
particularly those infecting the oral cavity. 
The overall objective of this study was to develop a novel mucosal vaccine that is 
safe, cost-effective and efficacious at inducing protective immunity against dental caries.  
A number of virulence factors have been identified as candidate vaccine antigens, most of 
which have been cloned and sequenced, and some have been tested with much promise. 
Since salivary immunoglobulin A (IgA) to various S. mutans adherence and aggregation 
factors has been showed to confer protection against S. mutans infection, induction of 
mucosal immunity has become the main target for dental caries vaccine development (37, 
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120, 122).  The target antigens used in this study were the S. mutans antigen A (AgA), a 
recognized candidate vaccine antigen, and its precursor the wall-associated protein A 
(WapA), a factor involved in colonization and build up of dental plaque.  Previously, 
WapA gene and the truncated agA gene had been cloned into a high expression vector for 
expression as Glutathione-S-Transferase fusion proteins to improve yield and facilitate 
purification (146).  However, considering that the costs associated with the extraction, 
purification and storage of recombinant antigens and antibodies can be an obstacle to 
mass immunization, it is necessary to explore alternative approach. 
With recent advances made in the construction of DNA vaccines comes the hope 
for a more economical way to immunize against infectious disease.  In the present study, 
genetic immunization using naked DNA vaccine was used as an alternative method of 
inducing mucosal immunity characterized by the induction of secretory IgA against S. 
mutans.  DNA vaccine is both potentially safer and more economical than conventional 
vaccines when considering the ease of isolation of plasmid DNA, low cost of mass-
production, stability at extreme temperatures, ease of administration, and potential for 
induction of long-lasting immunity without causing any severe side effects (1, 39).  
Therefore, the prospect of a DNA vaccine against dental caries is particularly attractive 
due to the high incidence of this disease in the world, with populations of low 
socioeconomic status being at the highest risk.   
DNA vaccines induce both specific antibody and cell-mediated immune responses 
(27).  However, their use has been mainly focused on viral infections (81).  DNA 
vaccines against bacterial infections have been limited to intracellular bacterial pathogens 
such as Mycobacteria spp. or Salmonella spp. where cytotoxic or a Th1 type T cells 
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confer protection (130).  Moreover, induction of mucosal immunity against extracellular 
bacterial infection where secretory IgA mediates resistance has been rarely studied.   
The feasibility of DNA vaccine efficacy was demonstrated in terms of inducing 
specific mucosal immunity against S. mutans, an extracellular bacterium, and relative 
immunogenicity of full-length and C-terminal truncated wapA was compared and 
evaluated. 
Further exploration was made to test the efficacy of two forms of vaccine; Gene 
versus Protein in inducing specific sIgA response.  The efficacy of co-immunization with 
genetic adjuvants at enhancing salivary IgA response was also investigated.  A number of 
cytokines have been identified as enhancing the mucosal IgA response to DNA vaccines, 
notably IL-5 in mice (102, 139).  Intranasal administration of recombinant adenovirus 
vectors expressing IL-5 has been shown to enhance secretory IgA response to the 
adenovirus in the lung (102).  Increased IgA response to Salmonella LPS has also been 
observed in mice immunized with the bacterial strain engineered to express murine IL-5 
(138).  IL-5 was chosen over other cytokines as it has been found to be the primary 
cytokine inducing the generation of IgA producing B cells in mice. 
Effects of co-immunization with either gene or protein of a CTB subunit were 
studied.  CTB is a proven adjuvant for the induction of a mucosal response to a protein-
based vaccine in mice (142).  Unlike CT and CTA subunits, CTB is not toxic, and hence 
has been considered as a good candidate adjuvant for human use (145).  Bergquist et al. 
(10), using recombinant CTB in intranasal immunization of humans, did not observe any 
systemic adverse reactions, but only local irritations of short duration at high doses 
(1,000 µg per dose) in all volunteers.  At a lower dose (100 µg), the local reaction was 
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mild and tolerable, and occurred only in approximately one third of the subjects. 
In a study conducted by Johansson et al. (52), 21 female volunteers were 
administered nasally 250 µg of recombinant CTB using an atomizer, and no apparent side 
effect was reported.  CTB was also found to be safe in the immunization of Israeli young 
adults against enterotoxigenic E. coli (16).  By using pcDNA-ctb as an adjuvant in DNA 
immunization, it was possible to not only compare the efficacy of protein versus DNA 
vaccine, but also that of protein versus DNA adjuvant.  The enhancement of mucosal 
immunity to protein conjugated with CTB was due to two functions of CTB: (1) 
transmucosal carrier, and (2) immuno-stimulatory molecule.  In immunization with 
pcDNA, delivery of pcDNA across the mucosal barrier is mediated by DMRIE-C, thus 
any enhancement obtained by co-immunization with pcDNA-ctb will be attributable to 
the strong immunogenic properties of CTB.   
Cloning of the truncated wapA genes, wapA-E and wapA-G, into the eukaryotic 
expression vector pcDNA3.1/V5/His-TOPO was completed, and the genes were shown to 
be inserted in the correct orientation.  To test the expression of the cloned genes, CHO 
cells were used as hosts in transfection studies. The cationic lipid pfx8 was used, as it has 
been reported by the manufacturer to work best for CHO cells. Indeed, transfection of 
CHO cells was successful, and the cloned genes were expressed as anticipated. It is 
noteworthy that the wapA-E gene product (WapA-E), corresponding to the S. mutans 
WapA, was expressed in the transfected cells and budding vesicles, probably from cells 
undergoing apoptosis, whereas the wapA-G gene product (WapA-G), corresponding to 
the S. mutans AgA, was found in both the cells and the surrounding medium.  
The differential expression of WapA and AgA may be attributable to the presence 
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of the hydrophobic C-terminal end of WapA, allowing this molecule to interact with 
hydrophobic components in the host cell membrane. The AgA protein is truncated in this 
hydrophobic region and hence is more soluble and may be released from leaky or lysed 
cells.   
Whether the genes are expressed as soluble or cell-and vesicle-associated 
proteins, it is reasonable to anticipate an antibody response, as previously obtained by 
immunization with the WapA and AgA proteins.  In fact, both cellular and humoral 
immune responses were obtained by immunization with DNA vaccines, indicating that in 
the host cells, the foreign proteins were processed both through the endogenous pathway 
of antigen processing, and presented associated with MHC-I, or through release and 
uptake by antigen-presenting cells for processing by the exogenous pathway and 
presentation in association with MHC-II (61).  The present study illustrated two ways by 
which foreign proteins could be released from the host cells.  The immunization study 
showed that it was feasible to induce a mucosal response to S. mutans antigen by 
intranasal administration of naked DNA vaccine containing the wapA gene or its 
truncated derivative agA gene.  Both DNA constructs induced antigen specific sIgA 
antibodies in the saliva of the immunized animals, with a higher antibody titre observed 
with pcDNA-wapA as compared to pcDNA-agA.   
It was hypothesized that due to its larger size and hydrophobicity, due to the 
presence of a membrane and wall-spanning region, WapA may be more immunogenic 
than its hydrophilic truncated derivative AgA.  Data from a previous in vitro transfection 
study showed that WapA was found expressed in budding vesicles (presumably apoptotic 
bodies), whereas AgA was diffused in the extracellular medium.  Such an occurrence in 
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vivo should facilitate the phagocytosis and processing of apoptotic bodies and the 
presentation of antigen peptides to T helper cells by macrophages.  This hypothesis was 
further supported by the sequence analysis of WapA and AgA using virtual matrices 
algorithms.   The results obtained revealed putative binding sequences within the 
hydrophobic C-terminal end of WapA, along with the rest of the sequences, based on 
MHC binding motifs for known major histocompatibility complex class II binding 
alleles.  Those predicted MHC class II ligands corresponded with promiscuous binding 
motifs associated with 51 MHC class II alleles; one of the most prominent promiscuous 
binders was located at residues 400 to 409, within the C-terminal end.  Those 
promiscuous binding motifs allow for a large degree of compatibility between the antigen 
peptide sequence and dimeric MHC II molecule (121).  The resulting peptide-MHC II 
complexes are delivered to the membrane for detection by CD4+ T cells and induce 
humoral immune responses (99). 
Most of the peptides presented by MHC class II molecules are derived from the 
endocytosis and processing of extracellular proteins (99, 122).  Previously, it was 
demonstrated by others that endogenous proteins produced by a DNA vaccine could be 
released from transfected cells and uptaken by antigen-presenting cells for processing by 
the exogenous pathway and presentation in association with MHC class II.  Moreover, in 
the host cells, endogenous antigens enter the MHC Class II processing and presentation 
pathways much more efficiently than the endocytosis and processing of the same protein 
from the extracellular compartment (12, 95, 115).  Another major factor affecting the 
antibody response is transfection efficiency (29, 43, 114).  The present study also 
demonstrated that transfection efficiency of HeLa cells was dependent on the ratio of 
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pcDNA:DMRIE-C starting at 1:1 (w/w) and reaching an optimal level at 1:5, then 
decreasing thereafter.  The decrease in transfection efficacy and expression was 
associated with cell death due to the toxicity of DMRIE-C at high dose. 
In addition to the above, the inhibition of S. mutans adherence to the culture 
vessel when grown in the presence of sucrose by a salivary antibody of  mice immunized 
with pcDNA-wapA, and not by the salivary antibody of the mice immunized with 
pcDNA-agA, further demonstrated that WapA was a better candidate vaccine antigen 
than AgA.  Dot immunobinding assay where the WapA in its larger precursor form 
showed a glucan-binding property, but not the 29-kDa C-terminal truncated version 
(wapA-G) encoding the AgA, supports this view.  These findings are in agreement with 
the previous data in an experiment where WapA, but not the AgA, showed a binding 
affinity to various dextran matrices (23).  The work presented here explores the feasibility 
of genetic immunization against S. mutans.  DNA vaccine containing the S. mutans wall-
associated protein A gene (wapA) were proven to be better immunogens than others 
which contained the truncated derivative corresponding to the antigen A gene (agA) for 
the reasons described above.   
 In the present study, we further evaluated if co-immunization with genetic 
adjuvant would enhance the levels of sIgA response elicited by the caries DNA vaccine 
containing the WapA gene.  Attempts were also made to compare the efficacy of DNA 
versus protein in inducing the WapA-specific sIgA response.  Our data shows that a DNA 
vaccine encoding WapA protein is less effective than a corresponding protein vaccine in 
inducing mucosal antibody response.  Furthermore, subsequent boosts with DNA vaccine 
were not capable of amplifying Ab memory generated by the DNA vaccine prime, 
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suggesting homologous DNA vaccine is not an efficient booster of immune memory. 
Specific salivary IgA response was transiently enhanced by co-immunization with 
IL-5 expressing plasmid, while comparatively steady increase was observed by a co-
immunization with plasmid containing the CTB gene.  This observation indicates that 
expressed CTB may have continuing adjuvant activity by enhancing presentation of 
expressed antigen released from transfected cells and by stimulating mucosal Th2-type 
cytokine responses, such as IL-5, leading to increased mucosal IgA production.  Antigen-
specific IgA response was improved by the action of pcDNA-il-5 expression, indicating 
immunomodulatory effect of the cytokine in improving isotype differentiation of B cells 
to mucosal IgA formation.  However, the IgA antibody response failed to be sustained, 
probably due to the lack of booster effect in generating continuous IL-5 as seen with 
pcDNA-wapA gene immunization.  
Prime-boost immunization regimen of pcDNA-wapA priming, followed by 
boosting with a WapA protein, showed considerable enhancement on the level that sIgA 
produced, almost as high as protein-protein vaccination.  Thus, pcDNA-wapA was shown 
to be a valid candidate primary vaccine and that subsequent natural exposure to S. mutans 
may provide the necessary boost to induce higher sIgA response. 
  It has been reported that plasmid DNA immunization predominantly induces a 
Th1-type cellular immune response (104) over a Th2 type immune response that 
produces humoral antibodies.  The lower salivary IgA immune response generated from a 
DNA vaccine might be due to the Th1-biased characteristic of the vaccine.  Insufficient 
memory response was consistently observed in other studies indicating that boosting may 
not efficiently stimulate the memory B cells with the DNA vaccine (70, 107, 119). 
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Indeed, the data demonstrated that intranasal immunization with a DNA vaccine followed 
by a boost with the corresponding protein vaccine showes a significant enhancement of 
the antigen-specific salivary sIgA response, a key factor for protective mucosal 
immunity.   
With recent advances in the understanding of B and T-cell memory, prime-boost 
vaccination strategies appear to create a synergistic effect from the two vaccines, and the 
quality and longevity of T-cell memory generated from DNA prime can be significantly 
enhanced by subsequent protein boosting.  From the experiments performed herein, we 
have been able to establish an alternative, novel DNA vaccine strategy of inducing 
mucosal immunity against S. mutans.  Dental caries induction involves multiple S. 
mutans proteins, and this study should serve as a model for the preparation of other gene 
constructs to include in a combination dental DNA vaccine.  The results obtained in this 
study will have an impact on future vaccine development, not only against S. mutans, but 
also against other pathogens utilizing the mucosal lining of the respiratory, gastro-
intestinal, and genito-urinary tract as a route of entry into the host.   
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